Aluminum oxide surface and interface molecules
Re-functionalizing aluminum oxide surfaces with carboxy-rich interfacial molecules addresses the issues of non-specific binding and orientation in biomolecule immobilization, enhancing the sensitivity and efficiency of diagnostic and industrial processes.
Patent Information
- Application Number
- JP2020566866
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-02-20
- Filing Date
- 2019-02-20
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2039-02-20
AI Technical Summary
Existing methods for immobilizing biomolecules on surfaces, such as aluminum oxide, often result in random adsorption leading to non-specific binding, steric hindrance, and poor orientation, which affects the sensitivity and efficiency of diagnostic and industrial processes like ELISA assays, microfluidic devices, and affinity chromatography.
Re-functionalization of aluminum oxide surfaces with interfacial molecules having a carboxy-rich domain that provides at least 5 free carboxyl groups, allowing for oriented immobilization of biomolecules through cross-linking agents and modified antibodies, ensuring stable binding and reducing non-specific interactions.
The solution enhances the sensitivity and specificity of diagnostic tests and industrial processes by maintaining the biological identity of biomolecules, reducing steric hindrance, and improving the efficiency of binding assays.
Smart Images

Figure 0007590873000003 
Figure 0007590873000004 
Figure 0007590873000005
Abstract
Description
[Technical field]
[0001] The present invention relates to aluminum oxide surfaces for binding biomolecules, such as proteins, for use in biomedical or industrial applications. The aluminum oxide surfaces are useful in applications such as diagnostic tests, affinity assays, and the isolation of biomolecules of interest from complex mixtures of biomolecules. [Background technology]
[0002] Over the past 50 years, the need for immobilization of biomolecules has increased significantly. Early efforts at immobilizing biomolecules were for diagnostic purposes such as ELISA assays. In such assays, antibodies were added to a polymer surface, e.g., a microtiter dish. Such surfaces were often polystyrene. Because the antibodies adsorbed randomly to the surface, only 5-7% of the immobilized antibodies were active. It was recognized that the sensitivity of the ELISA assay could be increased by orders of magnitude if the antibodies were oriented on the surface, so that the Fab fragments were oriented away from the surface, and the actual binding to the surface occurred via the Fc fragment. The need for oriented immobilized biomolecules has increased over time. Microfluidic devices, gene and protein microarrays, and immunodiagnostics in general, all benefit from oriented binding. Further analytical techniques, e.g., quartz crystal microbalance, surface plasmon resonance, and capillary electrophoresis, all benefit from improved oriented binding. Industrial processes such as affinity chromatography and affinity separations are more efficient when all the proteins are ordered on the surface. Equally important in all such fields is the need to prevent non-specific protein binding.
[0003] Protein adsorption onto oxides is of great importance in the field of bioceramics. Titania, alumina and zirconia are some of the more common oxide ceramics used in medical applications. Due to their excellent material properties, such as corrosion resistance, wear resistance, biocompatibility and mechanical strength, such materials are often used as biomaterials in medicine and dentistry. Protein adsorption onto oxides must take into account many material and environmental aspects, such as pH, microstructure, zeta potential and surface reactivity.
[0004] Proteins and other biological molecules, such as DNA and RNA, readily adsorb to surfaces, especially if they are charged. Attempts to improve the adsorption process include chemically or physically activating the surface to increase the number of charged sites. When considering materials such as alumina, which are highly catalytic, the adsorbed proteins may denature. There is ample evidence in the literature that this is a general phenomenon (Murray and Laband, 1979; Murray, 1980; Thurman and Gerba, 1988; Bowen and Gan, 1992). Because the adsorption process tends to be random, it can also result in inappropriate binding that can cause steric hindrance. Steric hindrance occurs when the molecules are improperly oriented or when they are too tightly packed. Non-specific binding can be a significant problem if the desired protein does not sufficiently cover the surface.
[0005] Polymer networks, such as hydrogels, retain water that can dissolve other molecules and make them available for reaction. Drawbacks of such techniques include the thickness of the film and diffusion processes, which can result in a slow response. Others have attempted to use thin polymer films to coat surfaces such as alumina. The polymer exposes pendant groups that are used to covalently bind biomolecules. This technique helps solve the problem of overly thick films, but can result in non-specific binding and poor orientation.
[0006] For glass and silica surfaces, the most common technique for covalently attaching biomolecules to surfaces is by the silanation process. In such a process, triethoxysilane derivatives are added to the surface, where the ethoxy groups react with silicon hydroxide groups at the surface, releasing ethanol to form a silated surface. The silicon in the triethoxysilane derivatives is bonded to a group that determines the surface properties. If this group is a long-chain alkane, the surface will be hydrophobic, whereas if this group is a methyl group, the surface will be hydrophilic. Such groups are then used to covalently attach biomolecules. In such cases, the biomolecules can be molecules such as antibodies, antigens, DNA, RNA, or avidin. Mao et al. (US Pat. No. 8,178,602) show such a system using R-PEG-silane as a preferred method of functionalizing surfaces. The R group in these examples is either biotin or methoxy. When Mao et al. use a mixture of two surface modifying molecules, the methoxy moiety is a neutral spacer, which reduces steric hindrance and allows more biotin to bind to avidin. Wagner et al. (U.S. Pat. No. 6,596,545) show that silanes can be used to attach linker molecules to glass, or thiols can be used to attach sulfur-containing linker molecules to gold surfaces. Such linkers can then be attached to biomolecules of interest. Coyne et al. (U.S. Pat. No. 6,589,799) demonstrate the activation of surface hydroxy groups of a support matrix material and the reaction of the activated hydroxy groups with aldehyde alkoxysilanes. Thus, derivatized aldehyde support matrix materials were useful for biomolecule immobilization and biological applications.
[0007] Other covalent attachment techniques include the use of calixarenes. The oxidized surface of the metal is first reacted with SiCl4 to produce a silicon chloride surface, which can react with the calixarenes to form stable structures on the surface that can have biomolecules covalently attached to them (Katz et al., U.S. Patent No. 6,951,690). Summary of the Invention [Problem to be solved by the invention]
[0008] The inventors have found that aluminum oxide surfaces can be reliably refunctionalized to produce interfacial molecules with carboxy-rich domains for biomedical applications. In particular, the interfacial molecules have molecular volumes between 2.2 and 25 nm 3 The interfacial molecule comprises a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxyl groups, whereby the interfacial molecule is immobilized on an aluminum oxide surface. The interfacial molecule is immobilized on the aluminum oxide surface and a biomolecule or a crosslinker is attached to the interfacial molecule. The aluminum oxide / interfacial molecule structure or device provides the basis for, for example, a diagnostic device or affinity assay, such that the biomolecule retains its biological identity and remains attached to the interfacial molecule in a stable manner. [Means for solving the problem]
[0009] In one broad aspect, the invention provides a device for use in binding to an analyte of interest. The device includes an aluminum oxide surface and an interfacial molecule immobilized on the aluminum oxide surface. The interfacial molecule has a molecular volume of 2.2 to 25 nm. 3 The interfacial molecule comprises a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby immobilizing the interfacial molecule on an aluminum oxide surface.
[0010] i) a cross-linking agent for binding to the analyte; ii) a biomolecule specific for the analyte, bound to the interface molecule by one or more covalent bonds; iii) a biomolecule in the form of an engineered antibody that binds to the interface molecule via a first antigenic determinant specific for the interface molecule and has a second antigenic determinant specific for the analyte; and iv) a biomolecule in the form of a modified antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte. One of these bonds to the interface molecule.
[0011] The invention also extends to an interfacial complex capable of being immobilized on an aluminum oxide surface for use in binding to an analyte of interest. The interfacial complex has a molecular volume of between 2.2 and 25 nm 3 The surface molecule includes a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxyl groups, thereby allowing the surface molecule to be immobilized on an aluminum oxide surface. i) a cross-linking agent attached to the interface molecule for binding to the analyte of interest; ii) a biomolecule specific for the analyte of interest, attached to the interface molecule by one or more covalent bonds; iii) a biomolecule in the form of an engineered antibody that binds to the interface molecule via a first antigenic determinant specific for the interface molecule and has a second antigenic determinant specific for the analyte of interest; and iv) a biomolecule in the form of an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. The present invention further includes one of the following:
[0012] In another broad aspect, the invention provides a diagnostic system or kit for testing whether binding has occurred to an analyte of interest. The diagnostic system or kit comprises: 1) an aluminum oxide surface; and a molecular volume of 2.2 to 25 nm. 3 an interfacial molecule comprising a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby being capable of being immobilized on an aluminum oxide surface; and 2) i) a cross-linker bound to the interface molecule for binding to the analyte; ii) a biomolecule specific for the analyte, bound to the interface molecule by one or more covalent bonds; iii) a biomolecule in the form of an engineered antibody that binds to the interface molecule via a first antigenic determinant specific for the interface molecule and has a second antigenic determinant specific for the analyte; and iv) a biomolecule in the form of a modified antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte. Contains one of the following:
[0013] In some of the above embodiments, the interfacial molecule and one of (i), (ii), (iii), and (iv) are immobilized on the aluminum oxide surface, while in other embodiments, the interfacial molecule and one of (i), (ii), (iii), and (iv) are formed as an interfacial complex and contacted with the analyte prior to immobilization on the aluminum oxide surface.
[0014] Some embodiments of the diagnostic system or kit provide a visual diagnostic device, in which an aluminum oxide surface is formed on a reflective metal capable of developing color when coated with a porous layer of aluminum oxide, the aluminum oxide surface being a porous anodized surface, in which, when contacted with a sample to test for an analyte, a color change is detected upon binding of the analyte to either the crosslinker in the presence of (i) or the biomolecule in the presence of (ii), (iii) or (iv) to indicate the presence of the analyte.
[0015] The invention also extends to a method of testing whether binding has occurred to an analyte of interest, the method comprising: a) forming an aluminum oxide surface having immobilized interfacial molecules, the interfacial molecules having a molecular volume of 2.2 to 25 nm 3a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby immobilizing the interfacial molecule on an aluminum oxide surface, the interfacial molecule comprising: i) a cross-linking agent for binding to the analyte; ii) a biomolecule specific for the analyte; iii) a biomolecule in the form of an engineered antibody having a first antigenic determinant specific for an interface molecule and a second antigenic determinant specific for an analyte of interest; iv) a biomolecule in the form of an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. a step, b) contacting the surface of a) with a sample to test for the analyte; and c) detecting the presence of the analyte upon binding of the analyte to the surface of a). Includes.
[0016] In some embodiments, the invention extends to a method of testing whether binding has occurred to an analyte of interest, the method comprising: a) forming an aluminum oxide surface; b) forming an interfacial complex capable of bonding to an aluminum oxide surface, the interfacial complex having a molecular volume between 2.2 and 25 nm 3 and an interfacial molecule comprising a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby allowing the interfacial molecule to be immobilized on an aluminum oxide surface, the interfacial molecule comprising: i) a cross-linking agent for binding to the analyte; ii) a biomolecule specific for the analyte; iii) a biomolecule in the form of an engineered antibody having a first antigenic determinant specific for an interface molecule and a second antigenic determinant specific for an analyte of interest; and iv) a biomolecule in the form of an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. a step, b) contacting the interfacial complex of a) with a sample and testing for the analyte; c) contacting the sample and the interfacial complex of b) with an aluminum oxide surface; and d) detecting the presence of the analyte upon binding of the analyte and the interfacial complex to the aluminum oxide surface. Includes.
[0017] In some embodiments of the above method, an aluminum oxide surface is formed on a reflective metal capable of developing color when coated with a porous layer of aluminum oxide, the aluminum oxide surface being a porous anodized surface, in which when contacted with a sample to test for an analyte, a color change is detected upon binding of the analyte to either the crosslinker in the presence of (i), or the biomolecule in the presence of (ii), (iii), or (iv), indicating the presence of the analyte.
[0018] In some embodiments of the above devices, diagnostic systems, kits or methods, the carboxy-rich domain comprises: Molecular volume: 2.2-25 nm 3 At least 10 free carboxyl groups in Molecular volume: 2.2-25 nm 3 At least 20 free carboxyl groups in Molecular volume: 2.2-17 nm 3 At least 10 free carboxyl groups in Molecular volume: 2.2-17 nm 3 At least 20 free carboxyl groups in Molecular volume: 7.0-17 nm 3 At least 10 free carboxyl groups in Molecular volume: 7.0-17 nm 3 At least 20 free carboxyl groups in results.
[0019] In some embodiments of the above devices, diagnostic systems, kits or methods, The crosslinker may be covalently bonded to the interfacial molecules or The biomolecules are covalently attached to the interfacial molecules by a crosslinker, or The interfacial molecule and the biomolecule are modified in amino acid sequence so that the interfacial molecule and the biomolecule are linked by peptide bonds, or The interface molecule is a modified or synthetic protein, polypeptide or antibody incorporating a carboxy-rich domain, or the biomolecule is an engineered antibody having a first antigenic determinant specific for an interface molecule and a second antigenic determinant specific for an analyte of interest; or The biomolecule is an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest.
[0020] In some embodiments, the crosslinker is covalently attached to the interface molecule. In other embodiments, the biomolecule is covalently attached to the interface molecule by the crosslinker. In other embodiments, the interface molecule and the biomolecule are modified in amino acid sequence such that the interface molecule and the biomolecule are linked by a peptide bond. In yet further embodiments, the interface molecule is an engineered protein, polypeptide, or antibody incorporating a carboxy-rich domain.
[0021] In some embodiments, the interfacial molecules are formed on the aluminum oxide surface as a continuous or discontinuous coating, as delineated dots or lines, or as an array.
[0022] In some embodiments, the interfacial molecule is one of a variety of types of interfacial molecules spaced apart on the aluminum oxide surface, and the biomolecule is bound to one of the types of interfacial molecules.
[0023] In some embodiments, the aluminum oxide surface is formed on a substrate in the form of particles, powders, films, slides, strips, beads, magnetic beads, magnetic particles, or a coating.
[0024] In some embodiments, the aluminum oxide surface is formed by sputtering, evaporating, casting or extruding aluminum metal or an aluminum alloy, which is further anodized to form a porous anodized aluminum oxide surface.
[0025] In some embodiments, the aluminum oxide surface is formed on the substrate by RF sputtering, reactive sputtering, or chemical vapor deposition of aluminum oxide.
[0026] In some embodiments, the interface molecule comprises one or more of the amino acids selected from the group consisting of aspartic acid (Asp), glutamic acid (Glu), and gamma-carboxyglutamic acid (Gla).
[0027] In some embodiments, the interface molecule is a vitamin K dependent protein, a fragment thereof comprising a Gla domain, or a fragment thereof comprising a modified Gla domain.
[0028] In some embodiments, the interface molecules and biomolecules are formed as molecules engineered to contain a carboxy-rich domain, such as a protein, polypeptide, antigen, antibody, carbohydrate, aptamer, or lipid.
[0029] In some embodiments, the carboxy-rich domain comprises a Gla domain of a vitamin K dependent protein or a fragment or derivative thereof, and the modified molecule comprises Protein A, fragment B of Protein A, or an IgG molecule.
[0030] In some embodiments, the interface molecule is a protein, a Gla domain of a protein, or a modified Gla domain of a protein, in which one or more of the Gla residues are substituted with Glu, Asp, Glu-Glu, Glu-Asp, Asp-Glu, or Asp-Asp, wherein the protein is selected from the group consisting of prothrombin, prothrombin fragment 1, protein S, coagulation factor IX, factor X, factor VII, protein C, matrix Gla protein, and bone Gla protein.
[0031] In some embodiments, the biomolecule is a member of a binding pair selected from the group consisting of antibody-antigen, antibody-hapten, enzyme-substrate, enzyme-receptor, toxin-receptor, protein-protein, avidin-biotin, aptamer-aptamer target, and drug receptor-drug.
[0032] The present invention also relates to the use of an interfacial molecule for refunctionalizing an aluminum oxide surface for use in biomedical applications, the interfacial molecule having a molecular volume between 2.2 and 25 nm 3 The use of the interfacial molecule includes a polypeptide having at least one carboxy-rich domain that provides at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids that contain two or more carboxy groups, thereby enabling the interfacial molecule to be immobilized on an aluminum oxide surface. [Brief description of the drawings]
[0033] [Figure 1]Diagram of the structural domains of the vitamin K-dependent proteins prothrombin (PT), factor IX (FIX), factor X (FX), factor VII (FVII), protein C (PC), protein S (PS), matrix Gla protein (MGP), and bone Gla protein (BGP). The legend indicates the protein components. Proteolytic cleavage sites are indicated by thin arrows where cleavage occurs to generate the mature protein structure, and by thick arrows where cleavage sites are associated with enzymatic activation. Image by Furie B and Furie BC (Furie and Furie, 1988). [Diagram 2] 3D structure of prothrombin. There are 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein (UnitProt Consortium, 2017a). This forms an 8.3 nm3 carboxyglutamine domain (carboxy-rich Gla domain) at the base of the structure where binding to the alumina surface occurs. [Diagram 3] 3D structure of human coagulation factor IX. There are 12 Gla residues located at positions 7, 8, 15, 17, 20, 21, 26, 27, 30, 33, 36 and 40 of the protein. Additional metal binding sites are at positions 1, 2, 47, 48, 50, 64, 235, 237, 240, 242 and 245 (UnitProt Consortium, 2017b). This forms a 17.0 nm3 carboxyglutamine domain at the base of the structure where binding to the alumina surface occurs. [Figure 4] The 3D structure of Protein S. There are 11 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29, 32 and 36 (UnitProt Consortium, 2017c). This forms a 12.3 nm3 carboxyglutamine domain at the base of the structure where binding to the alumina surface occurs. [Diagram 5]Figure 3D structure of modified fragment 1 of factor II. There are 10 Asp residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain of 8.7 nm3 at the base of the structure where binding to the alumina surface occurs. [Figure 6] Figure 1 shows a surface charge map of the 3D structure of modified fragment 1 of factor II. There are ten Asp residues in place of the ten Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 7] Figure 3D structure of modified fragment 1 of factor II. There are ten (Asp-Asp) residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain of 7.7 nm3 at the base of the structure where binding to the alumina surface occurs. [Figure 8] Figure 1 shows a surface charge map of the 3D structure of modified fragment 1 of factor II. In place of the 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein, there are 10 (Asp-Asp) residues. This forms a carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 9] Figure 3D structure of modified fragment 1 of factor II. There are 10 (Asp-Glu) residues replacing Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain of 8.5 nm3 at the base of the structure where binding to the alumina surface occurs. [Figure 10]Figure 1 shows a surface charge map of the 3D structure of modified fragment 1 of factor II. There are ten (Asp-Glu) residues replacing the ten Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 11] Figure 3D structure of modified fragment 1 of factor II. There are 10 (Glu-Asp) residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a 12.5 nm3 carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 12] Figure 1 shows a surface charge map of the 3D structure of modified fragment 1 of factor II. There are ten (Glu-Asp) residues replacing the ten Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 13] Figure 3D structure of modified fragment 1 of factor II. There are 10 (Glu-Glu) residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain of 11.8 nm3 at the base of the structure where binding to the alumina surface occurs. [Figure 14] Figure 1 shows a surface charge map of the 3D structure of modified fragment 1 of factor II. There are ten (Glu-Glu) residues replacing the ten Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 15]Figure 3 shows the 3D structure of bovine factor II fragment 1. There are 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a 7.0 nm3 carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 16] Figure 1 shows a surface charge map of the 3D structure of bovine factor II fragment 1. There are 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein, which form a carboxy-rich domain at the base of the structure where binding to the alumina surface occurs. [Figure 17] Figure 3D structure of human factor II fragment 1 with modifications added to the carboxyl terminus of the IgG heavy chain (Asp instead of Gla). There are 10 Asp residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This creates a carboxy-rich domain of 3.6 nm3 at the base of the IgG structure, allowing binding to alumina surfaces. [Figure 18] Figure 1 shows a surface charge map of the 3D structure of fragment 1 with modifications of human factor II (Asp instead of Gla) made to the carboxyl terminus of the IgG heavy chain. There are 10 Asp residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This creates a carboxy-rich domain at the base of the IgG structure, allowing binding to alumina surfaces. [Figure 19] Figure 3D structure of human factor II fragment 1 with a modification (Glu instead of Gla) added to the carboxyl terminus of the IgG heavy chain. There are 10 Glu residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This creates a carboxy-rich domain of 3.7 nm3 at the base of the IgG structure, allowing binding to alumina surfaces. [Figure 20]Figure 1 shows a surface charge map of the 3D structure of fragment 1 with a modification of human factor II (Glu instead of Gla) added to the carboxyl terminus of the IgG heavy chain. There are 10 Glu residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This creates a carboxy-rich domain at the base of the IgG structure, allowing binding to alumina surfaces. [Figure 21] Figure 3D structure of fragment B of protein A bound to the first 35 amino acids of human factor II fragment 1. There are 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This forms a 2.2 nm3 carboxy-rich domain at the base of the fragment B structure, allowing binding to alumina surfaces. [Figure 22] Figure 1 shows the surface charge map of the 3D structure of fragment B of protein A binding to the first 35 amino acids of human factor II fragment 1. There are 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein, which form a carboxy-rich domain at the base of the fragment B structure, allowing binding to the alumina surface. [Diagram 23] FIG. 1 is a schematic diagram showing an aluminum oxide surface with a prothrombin (FII) interfacial molecule immobilized on the surface via the Gla (carboxy-rich) domain. FII is modified with a cross-linking agent, e.g., glutaraldehyde, to attach a biomolecule, e.g., an antigen. The antigen is found to bind to its specific antibody. Example 1 is representative of this diagram. In Example 1, the linker is glutaraldehyde, the antigen is from influenza B, and the target antibody is anti-Influenza B virus. [Figure 24]FIG. 1 is a schematic diagram showing an aluminum oxide surface with fragment 1 of the prothrombin (Frag 1) interfacial molecule immobilized to the surface via the Gla domain. Frag 1 is modified with a crosslinker to bind a biomolecule, shown as an antigen that binds to its specific antibody. Example 5 is representative of this diagram, where the linker is glutaraldehyde, the antigen is from Hepatitis B virus, and the target antibody is an anti-Hep B antibody. [Diagram 25] Schematic diagram showing an aluminum oxide surface with a factor IX (FIX) interfacial molecule immobilized on the surface via the Gla domain. FIX is modified with a crosslinker to bind a biomolecule, shown as an antigen, which binds to this specific antibody. For example, the linker can be glutaraldehyde, the immobilized antigen can be influenza B, and the antibody can be anti-influenza B. [Figure 26] Schematic diagram of an aluminum oxide surface on which is immobilized a fragment B of Protein A modified to incorporate Frag 1 of FII into its structure, thereby binding the Gla domain to the aluminum oxide surface. The modified fragment B of Protein A forms an interface molecule that binds to a biomolecule, shown as an antibody that binds to this specific antigen. For example, the immobilized antibody may be from anti-influenza B and the antigen may be influenza B. [Figure 27] Schematic diagram of an aluminum oxide surface with an antibody (IgG) modified to incorporate the Gla domain of fragment 1 of FII at the carboxyl terminus of the Fc structure and attached to the surface via the Gla domain. The modified antibody is shown to bind to its specific antigen. For example, the Fab may be anti-influenza B and the target antigen may be from influenza B. [Figure 28]FIG. 1 is a schematic diagram showing an aluminum oxide surface with an antibody (IgG) modified to incorporate the Gla domain of fragment 1 of FII at the carboxyl terminus of its Fc structure and attached to the surface via the Gla domain. The modified antibody is known to bind to its specific antigen. A secondary antibody is known to bind to a target antigen that can be used to amplify the signal. The secondary antibody can be unmodified or modified with a conjugated enzyme or radiolabel to amplify the signal from across the device. For example, the Fab can be anti-testosterone, the target antigen can be testosterone, and the amplifying antibody can be anti-testosterone. [Figure 29] Schematic diagram showing an aluminum oxide surface with both prothrombin fragment 1 and prothrombin (FII) as two types of interface molecules bound to the surface via their Gla domains. A cross-linking agent, e.g. glutaraldehyde, is added to bind biomolecules, e.g. antigens. In this device, one interface molecule (Frag 1) is used to act as a spacer between the other interface molecule (FII) to reduce factors such as steric hindrance. The antigen and an antibody specific for the antigen (not shown) are bound to the interface molecule (FII) that is least sterically hindered and is furthest from the surface. For example, the immobilized antigen can be Hep B virus antigen, and a linker capping agent (e.g. lysine) can be added after antigen binding to prevent non-specific protein binding. [Figure 30A] 3 is a schematic diagram showing the use of an interface complex comprising an interface molecule and an antibody. The complex is an engineered antibody with a carboxy-rich domain at the Fc terminus, or an antibody Fc-conjugated with a carboxy-rich domain via the carboxyl terminus, which is used to capture an antigen as an analyte in a test sample. An example of this type of engineered antibody is the Gla domain of a vitamin K-dependent protein attached to the Fc terminus of an IgG antibody. The antigen is contacted with an aluminum oxide surface, whereby the carboxy-rich domain of the engineered antibody bound to the antigen binds to the alumina surface, and is separated from the solution. FIG. 30A shows the engineered antibody in solution with a mixture of proteins. [Figure 30B]FIG. 30B shows binding of the modified antibody to this specific antigen. [Figure 30C] FIG. 30C shows binding of the modified antibody-antigen complex to an aluminum oxide surface via the carboxy-rich domain. [Figure 30D] Figure 30D shows the separation of the protein of interest from the mixture by removing the aluminum oxide surface from the solution. The aluminum oxide surface is configured as a visual diagnostic device to detect antigen binding by a color change in Figure 30D. As an example, the Fab may be anti-albumin and the target protein may be albumin. [Figure 31A] 31A-31C are schematic diagrams showing an aluminum oxide surface with immobilized interfacial molecules, such as prothrombin (FII). The FII molecules are modified with a cross-linking agent, such as glutaraldehyde, as shown in FIG. 31A. [Figure 31B] In FIG. 31B, the surface is immersed in a sample, for example urea. [Figure 31C] If the analyte protein is present in the sample, it will bind to the glutaraldehyde interfacial molecule, as shown in Figure 31C. [Figure 31D] Removal of the surface from the sample removes proteins bound to the interfacial molecules by the crosslinker, as shown in Figure 31 D. The aluminum oxide surface is configured as a visual diagnostic device to detect protein binding by a color change, as shown in Figure 31 D. [Figure 32A] 32A is a schematic diagram showing an interface complex including an interface molecule and an antibody as an engineered antibody. An interface molecule, e.g., fragment 1 of factor II, is immobilized on an aluminum oxide surface. The antibody is engineered with two different Fab antigenic determinants, Fab1 and Fab2, as shown in FIG. 32A. Engineered antibodies can be generated by genetic engineering or wet chemistry by techniques known in the art. Fab1 is specific for the interface molecule and thereby binds to the interface molecule (e.g., the antithrombin component of antiprothrombin), while Fab2 is specific for the analyte of interest, e.g., an antigen. [Figure 32B]FIG. 32B shows the interfacial molecules on an aluminum oxide surface and the engineered antibody bound to the interfacial molecules via Fab1. [Figure 32C] Figure 32C shows a modified antibody that binds to the analyte antigen via Fab2. Alternatively, Fab2 can be bound to an additional biomolecule that functions as part of a binding pair, such as an antibody or an aptamer. For example, Fab1 can be anti-thrombin and Fab2 can be anti-prostate specific antigen, while the analyte is a prostate specific antigen. [Figure 33A] Schematic diagram showing the simultaneous use of two different sized interfacial molecules (high and low) bound to an aluminum oxide surface via their carboxy-rich domains. This arrangement allows two different biomolecules to be bound to the interfacial molecules, for example by a cross-linker such as an aptamer (Figure 33A). A linker can be added to the bulk solution of one interfacial molecule and to a separate solution of the other interfacial molecule. For example, the high interfacial molecule can be prothrombin and the low interfacial molecule can be fragment 1 of factor II. [Figure 33B] In FIG. 33B, the biomolecules are linked by a crosslinker. The biomolecules are different antigens that are recognized by different antibodies in the sample. For example, the target molecules can be two different hormones, such as hCG and LH. If the bottom layer is a reflective layer of aluminum oxide and serves as a visual assay, binding of different antibodies generates multiple color schemes depending on the antibodies present in the sample. For example, 0 represents no color change for no antibody binding, 1 or 2 represents a color change for binding of either antibody 1 or antibody 2, and 3 represents a color change for binding of both antibody 1 and antibody 1. In other embodiments, the biomolecules can be components of antibodies, aptamers, or alternative binding pairs. [Figure 34A] Schematic diagram showing binding of polyclonal modified IgG to an aluminum oxide surface. IgG molecules are modified with a carboxy-rich domain engineered at the carboxyl terminus of the Fc fragment to bind to an aluminum oxide surface. [Figure 34B]The Fab fragments are exemplified as Fab1 and Fab2 for binding to various epitopes of the antigen of interest (orientation 1 or orientation 2 as shown in FIG. 34B). In this way, the Fab fragments can be specifically bound to the antigen against which they were raised. By using polyclonal antibodies, binding is faster since the orientation of the antibody is not a critical factor. For example, Fab1 can be monoclonal 1 of prostate specific antigen (specificity site / orientation) and Fab2 can be monoclonal 2 of prostate specific antigen (specificity site / orientation) while the analyte is prostate specific antigen. [Figure 35A] 35A-35C are schematic diagrams showing examples for patterning interfacial molecules on an aluminum oxide surface. In FIG. 35A, aluminum is sputtered onto a surface in a pattern of lines using masking techniques known in the art. Aluminum is sputtered onto a thin film of tantalum on an underlying support, e.g., a slide. The aluminum can then be anodized to form a layer of aluminum oxide on the layer of tantalum oxide on the tantalum surface. Once anodization is complete, the aluminum oxide strip can emit interference colors that change upon addition of interfacial molecules, biomolecules, and analytes that bind to the biomolecules, respectively. Detection of the change in interference color can be detected by the naked eye in the visible spectrum and / or by a suitable detector, camera, etc., in or outside the visible spectrum. In some embodiments, such patterns of interference color changes can be achieved by printing the interfacial molecules as lines or patterns on a continuous aluminum oxide film of the underlying reflective layer. [Figure 35B] FIG. 1 is a schematic showing an embodiment for patterning interfacial molecules on an aluminum oxide surface. [Figure 36A] 35A and 35B show embodiments of diagnostic devices according to the present invention in which test sites are printed in a line or array as shown in FIGS. 35A and 35B, along with a barcode containing information about the array, assay, patient, etc. for reading by a barcode reader. [Figure 36B]FIG. 35A shows an embodiment of a diagnostic device according to the present invention in which test sites are printed in a line or array as shown in FIGS. 35A and 35B along with a QR code containing information about the array, assay, patient, etc. for reading by a smartphone. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] Certain terms used in the specification and claims are defined and clarified below.
[0035] The term "biomolecule" includes molecules that interact with biological systems. In general, biomolecule (or biological molecule) is a term that refers to molecules or ions present in living organisms. Biomolecules include large macromolecules (or polyanions), such as proteins, carbohydrates, lipids, and nucleic acids (aptamers), or derivatives or fragments thereof. Biomolecules also include small molecules, such as primary metabolites, secondary metabolites, natural products, and derivatives thereof. Biomolecules are usually endogenous, but may be exogenous. For example, pharmaceuticals may be natural or semi-synthetic (biopharmaceuticals), or they may be completely synthetic, and as such are included in the term biomolecule. Biomolecules also extend to synthetic proteins, polypeptides, and peptides, synthetic DNA or RNA, synthetic lipids, and synthetic carbohydrates.
[0036] The terms "alumina" and "aluminum oxide" are used interchangeably herein and include oxides formed on the surface of aluminum or aluminum metal alloys, whether the oxide is natural or formed, for example, by sputtering or anodizing to form aluminum oxide. The aluminum oxide surface may be formed on a substrate or support, such as a particle, powder, bead, magnetic bead or particle, thin film, slide, strip, filter, or coating. The aluminum oxide surface may be formed by sputtering, RF sputtering, reactive sputtering, chemical vapor deposition, evaporation, casting, or extrusion of aluminum metal or an aluminum alloy, and may further be anodized to form a porous anodized aluminum oxide surface.
[0037] The terms "bioidentity" and "biological identity" are used interchangeably to refer to the structural and chemical properties of a biomolecule that make it recognizable or specific for binding to other biomolecules, cells, or tissues. For example, if an antigen is immobilized, it is said to retain its bioidentity if an antibody raised against this antigen in an animal model, in vitro system, or computational model binds to the antigen with the same specificity and sensitivity as the antibody has when it is free in solution. As used herein, bioidentity does not necessarily require that a biomolecule, such as an enzyme, retains biological activity; it is sufficient that the biomolecule is still recognized.
[0038] The term "domain" refers to a group of amino acids within a protein or polypeptide that is identifiable by a function, property or structure from other parts of the protein or polypeptide.
[0039] The terms "immobilization" or "immobilize" as used herein refer to the binding or attachment of one or more interfacial molecules to the aluminum oxide surface, whether by chemical bonding or not.
[0040] The terms "covalent binding," "covalent bonding," and "crosslinking" are used herein to refer to the formation of covalent bonds between an interfacial molecule and a biomolecule. Typically, when the biomolecule is a polypeptide, the interfacial molecule is covalently bonded by a crosslinker. Alternatively, when the interfacial molecule is modified to include a biomolecule, the covalent bond is by a peptide bond.
[0041] The term "polypeptide" refers to a chain of amino acids linked by peptide bonds, and as used herein includes proteins, whether naturally occurring or modified, fragments of such proteins, and amino acid sequences derived from such proteins or fragments.
[0042] The term "sample" as used herein includes any biological or environmental material suspected of containing one or more analytes of interest, including samples lacking the analyte such that the analyte tests negative. Biological samples include, for example, bodily fluids and organic matter such as food. Bodily fluids include, for example, whole blood, plasma, serum, sputum, cerebrospinal fluid, pleural fluid, tissue, fecal material, etc. Environmental samples include, for example, soil, sludge, water, etc. The sample may be processed, for example, centrifuged, extracted, and / or lysed, if cells are present. Alternatively, the sample may be placed directly in contact with a diagnostic device.
[0043] According to the present invention, the aluminum oxide surface is refunctionalized with an interface molecule that can be immobilized on the surface for use in biomedical applications. In some embodiments, the interface molecule can be activated by binding to a crosslinker, which can then be used to bind to an analyte of interest in a test sample. In other embodiments, the interface molecule can be bound to a biomolecule, which can then be used (directly or indirectly) to bind to an analyte of interest in a test sample. In some embodiments, the biomolecule is covalently bound to the interface molecule, either by a crosslinker or a covalent bond, e.g., a peptide bond. The interface molecule and the biomolecule can be modified together as an interface complex. In other embodiments, the biomolecule can be an engineered antibody, for example, with one antigenic determinant specific for the interface molecule and a second antigenic determinant specific for the analyte of interest or another biomolecule in the test sample. In other embodiments, the biomolecule can be an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest.
[0044] The interfacial molecules have a molecular volume of 2.2 to 25 nm 3 The interfacial molecule comprises a polypeptide having at least one carboxy-rich domain that provides at least five free carboxyl groups therein. The free carboxyl groups are provided by amino acids that contain two or more carboxyl groups, thereby immobilizing the interfacial molecule to the aluminum oxide surface. The bound biomolecule retains its biological identity when bound to the interfacial molecule.
[0045] For clarity, as defined herein and in the claims, complexes formed by binding of interfacial molecules to biomolecules exclude vitamin K-dependent proteins, such as end products of prothrombin.
[0046] In some embodiments, the carboxy-rich domain has a molecular volume of 2.2 to 25 nm 3 At least 10 free carboxyl groups or molecular volume 2.2 to 25 nm 3At least 20 free carboxyl groups or molecular volume 7.0 to 20 nm 3 At least 10 free carboxyl groups or molecular volume 7.0-17 nm 3 Provide at least 20 free carboxyl groups in the polymer.
[0047] i) Interfacial molecules or interfacial complexes with biomolecules According to the invention, interfacial molecules having a particularly high affinity for the aluminum oxide surface via one or more carboxy-rich domains are immobilized on the aluminum oxide surface, for example as a continuous or discontinuous coating, as delineated dots or lines, or as an array. The interfacial molecules can be immobilized as a coating on the aluminum oxide surface from a solution of the interfacial molecules in a suitable solvent, after which the solvent can be removed. Typically, the interfacial molecules contain one or more of the amino acids aspartic acid (Asp), glutamic acid (Glu) and gamma-carboxyglutamic acid (Gla) to form the carboxy-rich domain(s). Examples of interfacial molecules are vitamin K-dependent proteins, fragments thereof containing a carboxy-rich Gla domain, fragments thereof containing a modified Gla domain, or synthetic peptides forming one or more carboxy-rich domains. Interfacial molecules and biomolecules can be formed as modified molecules in which the carboxy-rich domain is contained in a protein, polypeptide, antigen, antibody, carbohydrate, aptamer, or lipid. For example, the carboxy-rich domain may comprise one or more Gla domains of a vitamin K dependent protein or a fragment or derivative thereof, and the modified molecule may comprise a biological molecule, such as protein A, fragment B of protein A, or an IgG molecule.
[0048] In embodiments in which one or more carboxy-rich domains are formed in the interfacial molecule as synthetic peptides, amino acids containing carboxy groups are positioned and spaced in the synthetic peptide to ensure that sufficient free carboxyl groups are exposed on the surface of the folded synthetic peptide, thereby ensuring that these are available for immobilization to an aluminum oxide surface. The ability to fold to expose free carboxyl groups on the surface of the folded synthetic peptide can be readily confirmed by molecular modeling, as demonstrated in the Examples below.
[0049] The size of the interface molecule will vary depending on the specific application of the immobilized interface and biomolecule. For example, if the biomolecule is a modified antibody with an interface molecule incorporated into the Fc fragment, the interface molecule is preferably sized to limit steric hindrance. For example, for an antibody with a heavy chain of about 50 kD in size, the interface molecule is preferably small in size, e.g., less than about 30 kD, and each of the one or more carboxy-rich domain portions, Gla domain portions, or modified Gla domain portions of the interface molecule provides at least five free carboxyl groups in about 50 consecutive amino acids. Examples of sizing the interface molecule according to IgG molecules are shown below in Examples 14 and 16-19.
[0050] The distance from the aluminum oxide surface can be adjusted by varying the size of the interfacial molecule. Prothrombin holds the immobilized entity at about 10 nm from the surface, while the fragment 1 domain of prothrombin holds the immobilized entity at about 3 nm from the surface. Using a suitable linker, the distance can be varied to hold the molecule at about 1 nm to about 40 nm from the surface.
[0051] The interfacial molecules can include various types of interfacial molecules spaced apart on an aluminum oxide surface to reduce steric hindrance, as shown, for example, in Figure 29. As shown in Figure 29, prothrombin is spaced apart from prothrombin fragment 1. Prothrombin is bound to a biomolecule, for example, an antigen.
[0052] The interface molecules immobilized on the aluminum oxide surface can be activated with a crosslinker to bind to the analyte of interest (as in FIG. 31) or to a biomolecule. Alternatively, the biomolecule and the interface molecule can be pre-associated as a complex using a crosslinker, and the complex is then immobilized on the aluminum oxide surface. Alternatively, the interface molecule and the biomolecule can be genetically engineered or wet-chemically modified to include an appropriate binding sequence of a carboxy-rich domain that, for example, attaches an antigen or antibody to the end of the molecule (e.g., the first 32 amino acids of human prothrombin: Ala-Asn-Thr-Phe-Leu-Gla-Gla-Val-Arg-Lys-Gly-Asn-Leu-Gla-Arg-Gla-Cys-Val-Gla). -Gla -Thr-Cys-Ser-Tyr-Gla-Gla-Ala-Phe-Gla-Ala-Leu-Gla-XXX (SEQ ID NO:1) ) to form on a large scale.
[0053] In some embodiments, the interfacial molecules are formed on the aluminum oxide surface as a continuous or discontinuous coating, as delineated dots or lines, or as an array, hi some embodiments, the aluminum oxide surface is formed on a substrate in the form of particles, powders, thin films, slides, strips, filters, beads, magnetic beads, magnetic particles, or a coating.
[0054] There are several Gla-containing proteins, including vitamin K-dependent proteins: Factor II, Factor VII, Factor IX, Factor X, Protein C, Protein S, Protein Z, osteocalcin, matrix Gla protein (MGP), bone Gla protein (BGP), GAS6 periostin, two transmembrane Gla proteins (TMGP), and two proline-rich Gla proteins (PRGP). The structures of some of these Gla domain proteins are shown in FIG. 1. The sequence listing provides Factor II (prothrombin) in SEQ ID NO: 1, Factor IX in SEQ ID NO: 2, and Protein S in SEQ ID NO: 3. The charge-to-mass ratio of each protein plays an important role in how these proteins diffuse to the surface of the substrate at low concentrations. The inventors have determined that the number, location, and density of free carboxyl groups are important for the binding of proteins to aluminum oxide surfaces. In particular, as presented below, the inventors have established that the volume of the carboxy-rich domain of the interfacial molecules and the density of free carboxyl groups (-COOH) in the carboxy-rich domain are factors that determine the binding of the interfacial molecules to aluminum oxide surfaces.
[0055] The volume of the Gla domain of fragment 1 of prothrombin was established using computer software. The model generated by I-Tasser was opened in Molsoft ICM-Pro. The protein region of interest was selected and other regions were hidden. Under the display settings, the option to measure the distance between two atoms was selected. Two points were then selected to generate the length, width, and height dimensions of the region of interest. The product of such dimensions yielded the volume of the Gla domain or charged region, depending on the molecule. Using the same software, the volume and density of free carboxyl groups were then established for the carboxy-rich domains of naturally occurring proteins, protein S, FIX, and fragment 1 of bovine prothrombin, as shown in Table 1 below. Similarly, volumes and densities of free carboxyl groups were established based on the basic structure of the Gla domain of prothrombin for various synthetic carboxy-rich domains, as shown in Table 1 and described more fully below. Such volumes ranged from 2.2 to 17 nm 3 The density of free carboxyl groups is in the range of 1.15 to 9.09 / nm 3 The volume range was 17 nm. 3 ) and a fusion protein of two naturally occurring domains, the Gla domain of prothrombin and the fragment B domain from protein A (2.2 nm 3 The volume of the synthetic carboxy-rich domain lies in the range between these two proteins. The density range is larger than that of the synthetic carboxy-rich domain (FII-frag 1-Asp, described below, 1.15 COOH / nm 3 ) and a fusion protein of two naturally occurring domains, the Gla domain of prothrombin and the fragment B domain from protein A (9.09 COOH / nm 3), and examples of other carboxy-rich domains exist in the range between such proteins. Multiplying the density in Table 1 by the volume gives the number of free carboxyl groups in the carboxy-rich domains, which ranges from 10 to 24 free carboxyl groups. Comparison of the synthetic protein constructs (see Figures 5-14) to Fragment 1 of Factor II (Figures 2 and 15-16) shows that the basic structure has exposed carboxyl groups in a general cluster. R The results show that the carboxy-rich domain is maintained by a carboxyl group, indicating that the synthetic construct forms a carboxy-rich domain that binds to the aluminum oxide surface in a manner nearly identical to that of the natural vitamin K-dependent molecule.
[0056] Based on the following and further established examples, including molecular modeling studies, carboxy-rich domains for binding to aluminum oxide surfaces have molecular volumes between 2.2 and 25 nm 3 At least 5 free carboxyl groups or a molecular volume of 2.2 to 25 nm 3 At least 10 free carboxyl groups or molecular volume 2.2 to 25 nm 3 At least 20 free carboxyl groups or molecular volume 2.2 to 17 nm 3 At least 10 free carboxyl groups or molecular volume 2.2 to 17 nm 3 At least 20 free carboxyl groups or molecular volume 7.0-17 nm 3 At least 10 free carboxyl groups or molecular volume 7.0-17 nm 3 Provide at least 20 free carboxyl groups in the polymer.
[0057] Human prothrombin contains 10 gamma-carboxyglutamic acid (Gla) residues in the NH2-terminal domain. The Gla residues occur in adjacent pairs or in close proximity to each other (residues 6, 7, 16, 19, 20, 25, 26, 29, 32) (Walz DA et al., 1977; UnitProt Consortium, 2017a). These 10 Gla residues, with 20 free carboxyl groups, span a distance of 8.3 nm. 3This occupies a space of 1 nm 3 Prothrombin gives a density of 2.4 carboxy groups per Ca 2+ It has a high affinity metal binding site for . Such a binding site is formed by two Gla residues in the polypeptide chain, which share a single bound metal ion. An intermolecular bridge is formed, stabilizing the tertiary structure of the protein. The high concentration of Gla residues in the NH2-terminal domain of prothrombin results in robust binding with specific orientation to aluminum oxide when used with an alumina surface as an interfacial molecule.
[0058] FIG. 2 shows the three-dimensional structure of prothrombin, which is the localized protein structure (8.3 nm). 3 ) portion. Like the interfacial molecule of the present invention, prothrombin is found to bind to aluminum oxide surfaces at the Gla domain, since Gla has a higher affinity for alumina surfaces compared to other amino acids. Prothrombin has a molecular weight of 72,000 Da, an isoelectric point in the range of 4.7-4.9, and a dissociation constant of approximately 1 μmol / L (Bajaj et al., 1975; Kotkow et al., 1993; Mann, 1976; UnitProt Consortium, 2017a).
[0059] Human prothrombin is a three-domain protein consisting of fragment 1, fragment 2 and thrombin. The Gla residues (10) are all located in fragment 1. It consists of 155 amino acid residues (human). The Gla residues are all located in the first 32 amino acid residues. Therefore, this moiety has a high affinity for alumina substrates. Such 10 Gla residues with 20 free carboxyl groups form a 8.3 nm 3 This occupies a space of 1 nm 3 This gives a density of 2.4 carboxy groups per unit area.
[0060] The carboxy-rich domain of the interface molecule can be formed by modifying the Gla domain of a vitamin K-dependent protein or a fragment of a vitamin K-dependent protein, as presented below and in the Examples that follow. The modification can be accomplished by genetic engineering techniques well known to those skilled in the art, or by wet chemistry.
[0061] Fragment 1 of factor II can be modified with dicarboxy amino acids, such as aspartic acid. This is shown in Figure 5, where there are 10 Asp residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This is based on the 8.7 nm structure. 3 10 Asp residues, which have 10 free carboxyl groups, form a carboxy-rich domain of 8.7 nm where binding to the alumina substrate occurs. 3 This occupies a space of 1 nm 3 A surface charge map of the 3D structure of modified fragment 1 of factor II (FIG. 6) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0062] Fragment 1 of factor II can be modified by a pair of dicarboxy amino acids, e.g., asparagine-aspartic acid. In Figure 7, there are 10 (Asp-Asp) residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This is based on a 7.7 nm 3 carboxy-rich domains of 8.7 nm where binding to the alumina substrate occurs. 3 occupies a space of 1 nm 3 The surface charge map of the 3D structure of modified fragment 1 of factor II (FIG. 8) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0063] Fragment 1 of factor II can be modified by a pair of dicarboxy amino acids, e.g., asparagine-glutamic acid. In Figure 9, there are 10 (Asp-Glu) residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This is due to the 8.5 nm base of the structure. 3 10 such Asp-Glu residues, with 20 free carboxyl groups, form a carboxy-rich domain of 8.5 nm where binding to the alumina substrate occurs. 3 occupies a space of 1 nm 3 The surface charge map of the 3D structure of modified fragment 1 of factor II (FIG. 10) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0064] Fragment 1 of factor II can be modified by a pair of dicarboxy amino acids, e.g., glutamine-aspartate. In Figure 11, there are ten (Glu-Asp) residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This is due to the 12.5 nm base of the structure. 3 10 such Glu-Asp residues, with 20 free carboxyl groups, form a carboxy-rich domain of 12.5 nm where binding to the alumina substrate occurs. 3 occupies a space of 1 nm 3 The surface charge map of the 3D structure of modified fragment 1 of factor II (FIG. 12) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0065] Fragment 1 of factor II can be modified by a pair of dicarboxy amino acids, e.g., glutamine-aspartate. In Figure 13, there are 10 (Glu-Glu) residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This is based on the 11.8 nm structure. 3 Glu-Glu residues form a carboxy-rich domain of 11.8 nm, resulting in binding to the alumina substrate. 3 occupies a space of 1 nm 3 The surface charge map of the 3D structure of modified fragment 1 of factor II (FIG. 14) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0066] Bovine prothrombin is a three-domain protein consisting of fragment 1, fragment 2 and thrombin. Figure 15 shows that the Gla residues (10) are all located in fragment 1, which consists of 156 amino acids. The Gla residues are all located in the first 33 amino acid residues. This part has a high affinity for alumina substrates. Such 10 Gla residues with 20 free carboxyl groups can form a 7.0 nm 3 This occupies a space of 1 nm 3 Pericarboxy R This gives a density of 2.86 groups. A surface charge map of the 3D structure of bovine fragment 1 of factor II (FIG. 16) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0067] The interface molecules and biomolecules can be formed as modified molecules by genetic modification techniques well known to those skilled in the art in such a way that the carboxy-rich domain is included in the protein, polypeptide, antigen, antibody, carbohydrate, aptamer or lipid. For example, fragment 1 of human factor II or a fragment of vitamin K-dependent protein containing a Gla domain can be added to the carboxy terminus of an IgG heavy chain to form a carboxy-rich domain at the base of the IgG structure, allowing the modified antibody to bind to an alumina substrate. Similarly, synthetic antigens can be generated by adding a carboxy-rich domain to the sequence of an antigen of interest to perform an immunoassay. For example, there are 5-7 dengue virus serotypes, and synthetic antigens specific for each serotype can be modified with a carboxy-rich domain. When arranged in a multiplex pattern on an aluminum oxide surface, diseases can be rapidly diagnosed.
[0068] The modification of human factor II (Asp instead of Gla) fragment 1 binds to the carboxyl group of the IgG heavy chain, as shown in FIG. R There are 10 Asp residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the modified fragment 1 protein. This is due to the 3.6 nm base of the IgG structure. 3 This allows the formation of carboxy-rich domains of 1 nm in diameter, which can be bonded to the alumina substrate. 3 Pericarboxy R This results in a domain with a density of 3.03 groups. R A surface charge map of the 3D structure of the terminally modified (Asp instead of Gla) fragment 1 of human factor II (FIG. 18) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0069] The modification of human factor II (Glu instead of Gla) fragment 1 can be added to the carboxy terminus of the IgG heavy chain as shown in Figure 19. There are 10 Glu residues in place of Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This adds 3.7 nm to the basis of the IgG structure. 3 This allows the formation of carboxy-rich domains of 1 nm in diameter, which can be bonded to the alumina substrate. 3 A surface charge map of the 3D structure of human factor II fragment 1 with a modification (Glu instead of Gla) added to the carboxy terminus of the IgG heavy chain (Figure 20) shows a surface charge density in the carboxy-rich domain that promotes binding to alumina.
[0070] The fragment B domain of protein A can be bound to the first 32 amino acids of human factor II fragment 1. There are 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein. This provides a 2.2 nm basis for the fragment B structure. 3 This allows the formation of carboxy-rich domains of 1 nm in diameter, which can be bonded to the alumina substrate. 3 A surface charge map of the 3D structure of Protein A fragment B, which binds to the first 32 amino acids of human factor II fragment 1 (FIG. 22), shows the surface charge density in the carboxy-rich domain underlying the fragment B structure that allows binding to alumina substrates.
[0071] Human factor IX (hFIX) is a vitamin K-dependent plasma serine protease that is involved in the intrinsic pathway of blood coagulation. In its preprozymogen form, this hFIX consists of 461 amino acids. During biosynthesis to its mature structure, the pre- and propeptides are removed. Mature hFIX contains 12 Gla residues near the NH2-terminus, resulting in a Gla-rich domain. This region of the protein is a membrane anchor domain with affinity for metal ions (Furie & Furie, 1988; 1992; Furie et al., 1979). There are also 12 other metal binding sites that may have affinity for alumina substrate surfaces (UnitProt Consortium, 2017b). Figure 3 shows the three-dimensional structure of hFIX. The image identifies a Gla-rich domain with high affinity for metals. This domain is located at 17.0 nm. 3 It has a volume of 1 nm and is located at the base of the structure where the bonding to the alumina substrate occurs. There are 24 carboxy groups in this domain, which is 1 nm 3 This gives a density of 1.4 carboxy groups per unit area.
[0072] The binding orientation of hFIX to the alumina substrate is at the Gla domain. In this orientation, the protein has a wide base and is therefore structurally stable. This suggests that the binding orientation is consistent, as the hFIX protein is unlikely to change orientation. This is desirable because a predictable and consistent binding orientation results in consistent properties of the immobilized protein. Factor IX has a molecular weight of 55,000 Da, an isoelectric point in the range of 4.2-4.5, and a dissociation constant of <1.0 μmol / L (Amphlett et al., 1978; Nelsestuen et al., 1978; Thompson, 1986; UnitProt Consortium, 2017b).
[0073] Protein S is a glycoprotein that acts as a nonenzymatic cofactor for activated protein C (APC) in the degradation of coagulation factors V / Va and VIIIa. This protein S has 11 Gla residues near the NH2 terminus, which are important for membrane binding and are the binding site to the alumina substrate. Protein S has a molecular weight of 69,000 Da, an isoelectric point in the range of 5.0-5.5, and a dissociation constant of 0.005 μmol / L (Lundwall et al., 1986; Walker, 1981; Sugo et al., 1986; UnitProt Consortium, 2017c). Figure 4 shows the three-dimensional structure of protein S and the schematic location of the Gla domain (residues 42-87). The Gla domain is located close to the NH2 terminus, suggesting that it is exposed to the outside of the structure and is the binding site of the protein to the alumina substrate. This is due to the fact that the 12.3 nm base of the structure is 3 carboxyglutamine domain, where binding to the alumina substrate occurs. There are 22 carboxy groups in this domain, which is 1 nm 3 This gives a density of 1.79 carboxy groups per unit area.
[0074] [Table 1]
[0075] ii) Aluminum oxide surface Aluminum oxide surfaces can take the form of aluminum oxides and hydroxides, including calcined alumina, various transition aluminas (e.g., gamma, eta, delta), aluminum oxide hydroxides (e.g., boehmite), and amorphous aluminas (e.g., natural oxides of aluminum, anodized aluminum, and aluminum alloys). In general, binding to interfacial molecules occurs to cationic surface sites by ligand exchange with protonated surface hydroxyl groups, or by electrostatic attraction between positively charged surface sites, e.g., exposed aluminum ions and polyanion groups.
[0076] The aluminum oxide surface may be formed on a substrate, such as a particle, powder, magnetic bead, thin film, slide or coating. The aluminum oxide surface may be formed by sputtering, RF sputtering, reactive sputtering, chemical vapor deposition, evaporation, casting or extrusion of aluminum metal or an aluminum alloy, and may be further anodized to form a porous anodized aluminum oxide surface.
[0077] iii) Biomolecules Biomolecules are broadly defined above. In affinity binding assays, biomolecules can be members of binding pairs: antibody-antigen, antibody-hapten, enzyme-substrate, enzyme-receptor, hapten-hormone, toxin-receptor, protein-protein, avidin-biotin, aptamer-aptamer target, protein-drug, and drug receptor-drug.
[0078] As used herein, the biomolecular binding partner or bioconjugate bound to the interfacial molecule is referred to as the analyte of interest when used in a diagnostic test for the binding pair.
[0079] In general, the bond between binding pairs is referred to as a molecular bond. Depending on the binding pair, the molecular bond can be a non-covalent bond, a reversible covalent bond, or an irreversible covalent bond. Biomolecules involved in molecular bonds generally include proteins, nucleic acids, carbohydrates, lipids, and small organic molecules, such as drugs, whether natural, biosynthetic, synthetic, or derivatized.
[0080] iv) Crosslinking Agent The interface molecules, or the modification / alteration of the interface molecules with biomolecules, can be activated using any number of homoreactive or heteroreactive bifunctional crosslinkers, including imidoesters, glutaraldehyde, carbodiimides, maleimides, haloacetyls, hydrazides, and any others commonly known to those skilled in the art. An example of a homoreactive bifunctional crosslinker is pentane-1,5-dial. An example of a heteroreactive bifunctional crosslinker is 3-[2-pyridyldithio]propionyl hydrazide. The interface can then be coupled to biomolecules, such as proteins / peptides, carbohydrates, nucleic acids, and lipids, by the crosslinker. This allows the bound proteins / peptides, carbohydrates, nucleic acids, and lipids to be retained on the surface, maintain their bioidentity, remain structurally intact, and thus be recognized as native substances, which allows them to interact with antigens, antibodies, aptamers, and the like. The crosslinker will vary depending on the chemistry of the interface molecules and biomolecules, as is well known in the art. A list of common crosslinking agents can be found at https: / / tools.thermofisher.com / content / sfs / brochures / 1602163-Crosslinking-Reagents-Handbook.pdf.
[0081] v) Anodizing Aluminum or anodizable aluminum alloy materials can be anodized to produce a barrier or porous alumina layer. The main determinants of the resulting anodic alumina film include the electrolyte type (Ono, Masuko 2003; Abd-Elnaiem, Gaber 2013), strength (i.e., concentration or pH) (Belwalkar et al. 2008; Araoyinbo et al. 2010; Yim et al. 2007), and temperature (Li, Zhang & Metzger 1998; Abd-Elnaiem, Gaber 2013; Yim et al. 2007) and potential (Zhu et al. 2011; Ono, Masuko 2003; Belwalkar et al. 2008; Rahman et al. 2012; Abd-Elnaiem, Gaber 2013; Yim et al. 2007). Such parameters control the porosity, via the pore size and pore wall thickness (Van Overmeere et al. 2010), and the dissolution and etching rate of the layer. Further processing during oxidation can include pre-treatment (Zhu et al. 2011) and post-treatment.
[0082] When alumina is soluble in electrolytes (e.g., oxalic acid, sulfuric acid, and phosphoric acid), Al 3+ dissolution of Al2O3 occurs, forming a porous alumina layer. In the early stages of anodization, a highly resistive Al2O3 barrier film is formed on the aluminum layer. Further anodization leads to the propagation of individual paths through the barrier film, which is a precursor to pore formation. This is followed by decomposition of the barrier film and the formation of a porous structure. Once the formation of the porous oxide is complete on the aluminum layer, anodization of the underlying layer occurs (e.g. Ta). When the barrier oxide layer is completely formed, the current density is approximately zero (Eftekhari 2008).
[0083] Of particular interest are porous anodized surfaces formed on reflective metals for use in visual assays. The aluminum oxide surface is formed on a reflective metal that is capable of developing color when coated with a porous layer of aluminum oxide. The aluminum oxide surface is anodized as described above to produce a porous anodized surface which, when contacted with a sample to test for an analyte specific for the biomolecule, upon binding of the biomolecule and the analyte, a color change is detected to indicate the presence of the analyte.
[0084] vi) Solvent Solvents suitable for use in immobilizing interfacial molecules to aluminum oxide surfaces are typically aqueous solutions, preferably with low salt content and lacking anions with high affinity for the alumina surface (e.g., phosphates, carboxylates, sulfates). Binding times may vary depending on surface coverage, solvent, and solution pH.
[0085] vii) Signal Amplification If the aluminum oxide surface is part of a colorimetric device, for example for visual assays, some applications can benefit from signal amplification, i.e., in the formation of the binding layer of the device, it is sufficient to cause a detectable color change. For example, if an antibody is bound to or modified with an interface molecule and the matching antigen is very small (e.g., less than 1.5 nm), there may not be a significant change in color upon antigen binding, since the change in film thickness may not be very large (typically more than 1.5 nm). To amplify the signal (i.e., detectable color change), a second antibody can be added to the surface after exposing the surface to a sample containing the antigen analyte of interest. The second antibody (specific for the antigen) binds to the antigen that is bound to the first antibody. This second antibody binding, which occurs only if the desired antigen binds to the first antibody, increases the film thickness, for example by about 7 nm. This increase in thickness causes a dramatic change in interference color, which can be detected.
[0086] An example of signal amplification is depicted in Figure 28, which shows an aluminum oxide surface, prepared as presented above, as a thin layer of aluminum oxide on a reflective layer underneath. An antibody (IgG) binds the Gla domain of fragment 1 of FII to the carboxyl group of its Fc structure. R The modified antibody is shown to bind to its specific antigen. The second antibody is shown to bind to the target antigen and can be used to amplify the signal. The second antibody can be unmodified or it can be modified with a conjugated enzyme or a radiolabel to amplify the signal from the entire device.
[0087] For example, signal amplification can be used to detect small molecules, such as hormone molecules. Testosterone (C 19 H 28 O2) has a molecular weight of 288 and a 19 carbon backbone. This testosterone is approximately 2 nm long and less than 1 nm wide, which defines the lower limit of detection for the interference color-based assay. To amplify the signal, a second antibody that recognizes the testosterone-antibody complex can be added to the system. If testosterone binds to the antibody, the second antibody also binds. This increases the optical path length by approximately 7-10 nm, which effectively amplifies the signal and allows detection of the hormone of interest.
[0088] viii) Kits and diagnostic uses In some embodiments, e.g. for diagnostic testing, the invention extends to a diagnostic system or kit comprising a diagnostic device having an aluminum oxide surface formed on a suitable substrate, e.g. a slide. In a visual assay or visual diagnostic device, the diagnostic device comprises an aluminum oxide surface on a reflective metal, e.g. tantalum, capable of developing color when covered with a porous layer of aluminum oxide. In such applications, the aluminum oxide surface is formed as a porous anodized surface. In some embodiments of a visual assay or visual diagnostic device, an interface molecule is formed on the aluminum oxide surface and a specific antigen is bound to the interface molecule. Using the specific antigen, the kit detects the presence of an antibody specific for the antigen (analyte) when contacted with a test fluid, e.g. body fluid, tissue, etc., as the device undergoes a visible change in color upon binding of the antigen and antibody.
[0089] In some embodiments of the visual assay or visual diagnostic device, the kit comprises a diagnostic device as presented above, but conjugated to a specific antibody. For some applications, the specific antibody is modified to include a carboxy-rich domain as an interface molecule. This kit allows for the detection of a specific antigen in a test liquid, due to a visible change in color of the device upon antigen binding.
[0090] In some embodiments of the visual assay or visual diagnostic device, the kit comprises a diagnostic device as presented above, but bound to a bispecific engineered antibody having a first antigenic determinant (Fab1) specific for an interface molecule and a second antigenic determinant (Fab2) specific for an analyte of interest, e.g., an antigen, in a test sample. This kit allows for detection of a specific antigen in a test liquid due to a visible change in color upon binding of the antigen to the engineered antibody. Dual antibody synthesis techniques are well known (see, e.g., Brinkmann, Ulrich et al.).
[0091] In some embodiments of the visual assay or visual diagnostic device, the kit comprises a diagnostic device as set forth above, but conjugated to an aptamer, which binds to its specific target molecule and produces a visible change in color.
[0092] Visual Assay or Visual Diagnostic Device In some embodiments, the kit comprises a diagnostic device as set out above, but coupled to a modified Protein A containing a carboxy-rich domain as an interface molecule, which binds to the Fc region of an antibody, ensuring proper orientation of the antibody so that its corresponding specific antigen can be detected by a visible change in color.
[0093] In some embodiments of the visual assay or visual diagnostic device, the kit comprises a diagnostic device as provided above, but where the interface molecule has been modified or activated by binding to a cross-linking agent that binds to a specific analyte of interest in the test sample (e.g., a protein in urine) resulting in a visible change in color. In some embodiments of the visual assay or visual diagnostic device, the kit comprises an aluminum oxide surface as set forth above, but the interface molecule and crosslinker or biomolecule are, for example, a cross-linking agent that is attached to or for attachment to an interfacial molecule and is capable of binding to an analyte of interest; or a biomolecule specific for the analyte of interest that is bound to or for binding to the interfacial molecule; or A biomolecule in the form of an engineered antibody that binds to or for binding to an interface molecule via a first antigenic determinant and has a second antigenic determinant specific for an analyte of interest. is formed separately from the aluminum oxide surface by forming one of
[0094] The components of the kit may be included separately from the interfacial molecule and combined prior to testing, or the interfacial molecule and crosslinker or biomolecule may be formed in the kit as an interfacial complex. The interfacial complex is contacted with a sample to test for the analyte, and then the sample and interfacial complex are contacted with an aluminum oxide surface. The kit detects the presence of the analyte by a visible change in color upon binding of the analyte and interfacial complex to the aluminum oxide surface.
[0095] In addition to the diagnostic device, such a kit typically includes a container to house the device, and one or more other components. The kit may include pharmaceutical or diagnostic grade components, such as crosslinkers, assay standards, test components, etc., in one or more containers. The kit may include instructions or labels encouraging or describing the use of the device or components. The instructions may include written instructions on or in association with the packaging of the components. The instructions may also include any oral or electronic instructions provided by any method, for example, for mixing one or more components of the kit and / or for isolating and analyzing a sample.
[0096] To facilitate unambiguous analyte quantification in a sample, the assay components may employ analyte standards, where the standard is a predetermined amount of analyte to be detected that is formed in the device to allow for quantification of the analyte. The standard may be analyzed to generate a standard curve that equates the amount of analyte to the amount of analyte present in the sample. In a visual assay, the standard may include a color swatch that pretests the diagnostic device to indicate negative and positive results.
[0097] The technique of protein printing is well known and can be used to print interfacial molecules, biomolecules and / or complexes of interfacial molecules and biomolecules (see, for example, Delaney, Joseph T et al., McWilliam I et al., and Li, J et al.). Protein printing, for example by an inkjet printer, can be used to deposit an array of different proteins to multiplex tests. Each protein emits a color that changes in the presence of their target molecule (e.g., antibody, antigen, aptamer, DNA standard or RNA standard). For example, immunoassays can be multiplexed by placing different proteins in specific patterns on an aluminum oxide surface. Such patterns can be in the form of lines, curves, circles, dots or complex patterns. They provide information about the various analytes in the test sample. The results are determined by the change in color of the patterns of the different printed parts. For example, multiple antigens can be attached to diagnostic surfaces characteristic of particular viruses, such as those that cause Chikungunya, Dengue Fever, Yellow Fever, and Zika. Diagnostic techniques identify not only the disease but also the serotypes present based on color changes in specific areas. This multiplex testing determines cases where a patient is infected with one or more viruses or serotypes from a single sample.
[0098] In some applications, analyte-specific binding to biomolecules can be detected using any suitable detector, depending on the type of test or assay to be performed. In general, the detector includes an illumination source and detection electronics. The light source can be sunlight, for example for point-of-care diagnostics, or other light sources, such as LEDs, lasers, and incandescent bulbs. Such sources can be used in combination with optical filters, polarizers, diffraction gratings, and other optical components that generate specific light spectral components. Other forms of radiation can be used, such as bioluminescence, fluorescence, and others. The excitation wavelength can be in the visible part of the spectrum (wavelengths 300-700 nm) or other wavelengths, such as infrared and ultraviolet. The absorbed, reflected, or re-emitted light can then be observed and / or detected using the naked eye (for visible wavelengths) or using light-sensitive detectors, such as photodiodes or photomultipliers, in combination with spectral and / or spatial filtering.
[0099] Sensitive detection methods are available where color changes are below the visual detection limit and cannot be detected by the naked eye. Digital image analysis, spectrophotometry, and other photon-counting detectors allow for analysis of changes in reflected wavelength. High resolution image acquisition and digital processing is a technique well understood in the art for common use in biological research to quantify and analyze color patterns. Quantification of visible color can be achieved by digital processing. To distinguish colors, plots can be created using the International Commission on Illumination (Commission Internationale de l'Ecla, CIE) color space, which allows for a 2D plot of chromaticity coordinates. Spectrophotometers can provide analysis beyond what is detectable by the human eye with full spectrum measurements of reflectance properties. At very low levels of light intensity, photon-counting detection devices (e.g., photomultipliers) can be used to measure the number of photons by increasing the signal before detection.
[0100] One example of a suitable detector is a reflectance spectrometer that measures the reflectance of a reflecting surface. Alternatively, the detector can be a camera or imaging device. Detection can be at the point of care, for example in a visual assay, or remote from the sample collection or patient site.
[0101] The method of the invention extends to a computer for data integration, analysis, storage and transmission, whereby the detected analyte-specific binding can be integrated with data acquired by any one of the data acquisition components. Such integrated binding and data can then be analyzed and stored by the computer for later use. The computer typically includes an operating system that accesses one or more algorithms and / or software to analyze the assay component data, e.g., by comparison to stored data or a standard curve, to determine the presence and / or amount of the analyte being tested. The raw data and / or the integrated and analyzed data are displayed on a display screen, e.g., a computer display or a cell phone, PDA, etc.
[0102] A barcode reader can be provided for automated entry of information about the assay components. The barcode reader can be combined with a barcode activation system, which identifies the test to be analyzed and automatically initiates one-point assay calibration for that particular test, reducing user error. Each individual assay component contains a unique barcode that is read and used to initialize the device so that the appropriate algorithm can be utilized. Exemplary embodiments of assay components according to the present invention are shown in Figures 36A (barcode) and 36B (QR code).
[0103] The diagnostic device may be configured as a sample apparatus, eg, a handheld device or a kit, that includes one or more of the components as described above.
[0104] ix)Application Aluminum oxide surfaces on which interfaces forming carboxy-rich domains are immobilized according to the present invention have a wide range of uses, including, for example, protein coatings on various surfaces for a variety of products in biomedical applications; coatings on anodic films for medical diagnostic devices such as visual immunoassays, coatings on anodic films for environmental monitoring; coatings on anodic films for food safety diagnostic devices; coatings on anodic films in microtiter plates for ELISA testing and the like; coatings on MEMS / NEMS for diagnostics, coatings on nanoparticles for targeted therapeutic delivery; coatings on nanoparticles for contrast imaging; alumina particles for column-based affinity separation applications; magnetic particles for affinity recovery of biomolecules and cells; research assays to verify the accuracy of antibodies prior to testing; coatings for plastic sample cups with lids to facilitate testing, and coatings on medical devices or implants, to name a few.
[0105] The invention is also illustrated by the following non-limiting examples. EXAMPLES
[0106] (i) Aluminum oxide surfaces and interfacial molecules as affinity devices Example 1 In this example, we demonstrate the binding of proteins (specifically viral antigens) to an alumina substrate immobilizing prothrombin as an interfacial molecule. The alumina substrate was produced by first sputtering tantalum to a thickness of 200 nm onto an amorphous support, followed by sputtering aluminum onto Ta to a thickness of 120 nm. The aluminum was converted to alumina by electrochemical oxidation (anodization), using phosphoric acid anodization at 8 V with an electrolyte of 0.4 M phosphoric acid until the current decayed to near 0 mA. This produced a layer of Al2O3 approximately 190 nm thick on top of a layer of Ta2O5 14 nm thick. The color of the produced device was gold when observed at 15° with white light through a polarizer. Prothrombin was placed on the alumina surface for 30 minutes in a 100% RH environment (10 μL of a 1 mg / mL solution) and then rinsed thoroughly with deionized water. After the device was air-dried, the color changed to rust. The device was then immersed in a 0.5% (v / v) glutaraldehyde solution supplemented with 25 mM phosphate buffer pH 6.9 for 60 minutes. After rinsing again with deionized water, influenza B virus antigen, Hong Kong 5 / 72 strain, was placed on the surface for 60 minutes (10 μL of a 1.75 mg / mL solution). The device was then rinsed with 25 mM phosphate buffer for 60 minutes and allowed to air dry, at which point the color changed to lavender. The color change was caused by an increase in the optical path length caused by the immobilization of the antigen.
[0107] Example 2 This example illustrates that proteins such as IgG do not bind to anodic alumina surfaces. A device was produced as in Example 1, and prothrombin was immobilized on two of the three imaged spots on the surface by the same procedure as described in Example 1. After immobilization of prothrombin, a rust color was observed. Antiprothrombin was added (10 μL of a 100 μg / mL solution) to one spot with prothrombin and the remaining empty spot for 15 minutes and rinsed with deionized water. The device was air-dried and then observed at 15° as in Example 1. A burgundy color spot was observed at the spot containing both the antigen (prothrombin) and the protein antibody (antiprothrombin). The color change indicated that the immobilized protein was recognized by the antibody, which bound to the protein and changed the total thickness of the protein layer. There was no observable color change on the bare anodic oxide surface to which antiprothrombin was added. This indicates that the protein did not bind to the anodic surface because there was not enough residual protein on the surface to change the optical path length of the light.
[0108] Example 3 This example shows how glutaraldehyde can be capped with an aminoprotein, specifically tris(hydroxymethyl)aminomethane, thereby rendering the immobilized protein specific by preventing binding to immobilized prothrombin.
[0109] The device was produced as described in Example 1, prothrombin was immobilized on the surface, and glutaraldehyde solution was added. The device was then immersed in 1×TBS buffer to cap any glutaraldehyde that could be bound. A layer of protein (specifically, IgG antibody, goat-produced anti-influenza B) was placed on the surface for 30 minutes and then rinsed with deionized water. The device was air-dried and then observed at 15°. There was no visible change in color observed. This lack of color change indicated that the optical path length was not changed by exposure to the added non-specific antibody. This is important to show that the device functions as an affinity substrate without false positives due to non-specific proteins.
[0110] Example 4 This example illustrates a visual assay for surface antibody-antigen complexes by binding the antigen to the prothrombin interface. A device was generated, prothrombin was immobilized on the surface, and a cross-linking agent was added as described in Example 1. A synthetic surface antigen of Hepatitis B (Hep B) was then bound to the prothrombin using the same procedure as in Example 1. After antigen binding, a rust color was observed.
[0111] The remaining glutaraldehyde was then capped with a solution of 0.1 M L-lysine in 0.3 M phosphate buffer pH 7.0 for 60 min. Finally, serum samples (n=20) were placed on the surface for 15 min and rinsed with deionized water. The device was allowed to air dry and then observed at 15°, revealing magenta spots. The color change indicated that the bound protein was recognized by the antibody, which bound to the protein and changed the total thickness of the protein layer.
[0112] In the above examples, the naturally occurring protein prothrombin is used as an interface to coat alumina. The prothrombin is then activated by homoreactive or heteroreactive bifunctional molecules to bind the protein of interest to the prothrombin. If an interface molecule (e.g., about 3 nm) is desired that is thinner than prothrombin (about 10 nm), fragment 1 of the prothrombin molecule can be used instead of prothrombin, as shown in the following examples. Glutaraldehyde or any other homoreactive or heteroreactive bifunctional molecules can then be used to bind the biomolecule of interest to fragment 1.
[0113] Example 5 This example illustrates the ability to form an antibody-antigen complex on a surface by binding an antigen to fragment 1 of FII. A device was produced as in Example 1, and fragment 1 was immobilized on the alumina surface instead of prothrombin. Fragment 1 was placed on the device surface for 30 minutes in a 100% RH environment (10 μL of a 0.3 mg / mL solution) and then rinsed thoroughly with deionized water. After air drying the device, the color changed to a light rust color. An antigen against the Hepatitis B virus was then bound to the surface using the same cross-linking procedure as in Example 1. A rust color was observed after immobilization of the Hepatitis B antigen.
[0114] The remaining glutaraldehyde was then capped with a 0.1 M L-lysine solution in 0.3 M phosphate buffer pH 7.0 for 60 min. Finally, anti-Hep B antibody was placed on the surface for 15 min (10 μL of a 100 μg / mL solution) and washed off with deionized water. The device was air-dried and then observed at 15°, where purple spots were observed. The color change indicated that the immobilized protein was recognized by the antibody, which bound to the protein and changed the total thickness of the protein layer.
[0115] Example 6 This example illustrates an interfacial molecule immobilized on an aluminum oxide surface and activated by binding the interfacial molecule to a crosslinker for use in binding to an analyte in a test sample. A device was produced as in Example 1 and prothrombin was immobilized at two points on the aluminum oxide surface. At one point, the prothrombin was activated by binding glutaraldehyde to the crosslinker as described in Example 1. The other point was not modified. Both points turned rust-colored. A solution of nonsense IgG (i.e., non-specific for prothrombin) was added to both points and left for 60 minutes, followed by a washing step and air drying. The point containing activated prothrombin bound to nonsense IgG, when shown in color, turned purple. The second point did not change color, indicating no binding had occurred. This example is illustrated diagrammatically in FIG. 31 and illustrates the use of a diagnostic test to detect protein in urine as a point-of-care device.
[0116] (ii) Engineered biomolecules with carboxy-rich interfaces Example 7 This example illustrates an interface molecule modified as an anchor protein with a carboxy-rich amino acid sequence for binding to an alumina surface. Here, the first 32 amino acids of fragment 1 from human factor II are modified and directly conjugated in a stable form to an aluminum oxide surface. The modified fragment 1 is attached to the alumina surface via a cluster of carboxy groups associated with the dicarboxy amino acid Asp. Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein are replaced with Asp. This halves the number of carboxy groups available for binding to the surface compared to native fragment 1 of Example 6. This replacement results in a carboxy-rich domain at the amino terminus of fragment 1, as shown in a computer model of the structure generated by protein folding software (Figure 5). The sequence listing of the modified Gla domain of the F1 fragment is provided in SEQ ID NO: 4. A computer model of the surface charge of the protein (Figure 6) supports this and shows the carboxy-rich domain of the basis of the modified interface molecule through which binding to the alumina substrate occurs.
[0117] Example 8 In this example, an interface molecule for binding to an alumina surface is illustrated, modified as an anchor protein with a carboxy-rich amino acid sequence. Here, the first 32 amino acids of fragment 1 from human factor II are modified and directly conjugated to an aluminum oxide surface in a stable form. The modified fragment 1 is attached to the alumina surface via a cluster of carboxy groups associated with the dicarboxy amino acid Asp (one dicarboxy amino acid). Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein are replaced with Asp-Asp. This preserves the number of carboxy groups available for binding to the surface compared to native fragment 1 of example 6. This replacement results in a carboxy-rich domain at the amino terminus of fragment 1, as shown in the computer model of the structure (Figure 7). The sequence listing of the modified Gla domain of the F1 fragment is provided in SEQ ID NO:5. A computer model of the surface charge of the protein (Figure 8) supports this and shows the carboxy-rich domain as the basis of the modified interface molecule.
[0118] Example 9 This example illustrates an interface molecule modified with a carboxy-rich amino acid sequence for binding to an alumina surface. The first 32 amino acids of fragment 1 from human factor II are modified for direct conjugation to an aluminum oxide surface in a stable form. The modified fragment 1 is bound to the alumina surface via a cluster of carboxy groups associated with the dicarboxy amino acid Asp-Glu. Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein are replaced with Asp-Glu. This preserves the number of carboxy groups available for binding to the surface compared to native fragment 1 of Example 6. This substitution results in a carboxy-rich domain at the amino terminus of fragment 1, as shown in the computer model of the structure (Figure 9). The sequence listing of the modified Gla domain of the F1 fragment is provided in SEQ ID NO: 6. A computer model of the surface charge of the protein (Figure 10) supports this and shows the carboxy-rich domain as the basis of the modified interface molecule.
[0119] Example 10 This example illustrates a modified interface molecule in which the first 32 amino acids of fragment 1 from human factor II are modified to allow direct conjugation to aluminum oxide surfaces in a stable form. Modified fragment 1 is attached to the alumina surface via a cluster of carboxy groups associated with the dicarboxy amino acid Glu-Asp. Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein are replaced with Glu-Asp. This preserves the number of carboxy groups available for binding to the alumina surface compared to native fragment 1 of Example 6. This substitution results in a carboxy-rich domain at the amino terminus of fragment 1, as shown in the computer model of the structure (Figure 11). The sequence listing of the modified Gla domain of the F1 fragment is provided in SEQ ID NO: 7. A computer model of the surface charge of the protein (Figure 12) supports this and shows the carboxy-rich domain as the basis of the modified interface molecule.
[0120] Example 11 In this example, further modified interface molecules are illustrated. The first 32 amino acids of fragment 1 from human factor II are modified to allow direct conjugation to aluminum oxide surfaces in a stable form. Modified fragment 1 is attached to the alumina surface via a cluster of carboxy groups associated with the dicarboxy amino acid Glu-Glu. Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein are replaced with Glu-Glu. This preserves the number of carboxy groups available for binding to the surface compared to native fragment 1 of example 6. This replacement results in a carboxy-rich domain at the amino terminus of fragment 1, as shown in the computer model of the structure (Figure 13). The sequence listing of the modified Gla domain of the F1 fragment is provided in SEQ ID NO: 8. A computer model of the surface charge of the protein (Figure 14) supports this and shows the carboxy-rich domain as the basis of the modified molecule.
[0121] Example 12 In this example, the interface molecule of fragment 1 from bovine factor II is illustrated. Bovine fragment 1 has an additional amino acid insertion at position 4 compared to human fragment 1. The use of bovine fragment 1 results in a carboxy-rich domain at the amino terminus of fragment 1, as shown in the computer model of the structure (Figure 15). The sequence listing of the modified Gla domain of the F1 fragment is provided in SEQ ID NO:9. A computer model of the surface charge of the protein (Figure 16) supports this, showing the carboxy-rich domain at the base of the molecule.
[0122] (iii) Genetically engineered or chemically derivatized proteins / antibodies having carboxy-rich domains Example 13 In this example, a carboxy-rich amino acid sequence from human factor II fragment 1 is used to chemically mutate or modify an antibody (here an IgG heavy chain) for direct conjugation to an aluminum oxide surface in a stable form. The modified molecule is attached or incorporated at the carboxy-terminus of the Fc fragment of the antibody. Gla located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein are replaced with Asp. This halves the number of carboxy groups available for conjugation to the surface compared to native fragment 1. This substitution results in a carboxy-rich domain at the amino-terminus of modified fragment 1, as shown in the computer model of the structure (Figure 17). The sequence listing of the modified Gla domain of the F1 fragment is provided in SEQ ID NO: 10. A computer model of the surface charge of the protein (Figure 18) supports this and shows the carboxy-rich domain of the basis of the modified molecule for conjugation to alumina.
[0123] Example 14 This example illustrates a chemically mutated or modified IgG heavy chain antibody for direct conjugation to an aluminum oxide surface in a stable form using a carboxy-rich amino acid sequence from human factor II fragment 1. The modified molecule is attached or incorporated at the carboxy-terminus of the antibody Fc fragment. Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the protein are replaced with Glu, which halves the number of carboxy groups available for surface conjugation compared to native fragment 1. This substitution results in a carboxy-rich domain at the amino-terminus of fragment 1, as shown in the computer model of the structure (Figure 19). The sequence listing of the modified Gla domain of the F1 fragment with a heavy chain IgG antibody is provided in SEQ ID NO: 11. A computer model of the surface charge of the protein (Figure 20) supports this and shows the carboxy-rich domain of the basis of the modified molecule for conjugation to an alumina surface.
[0124] Example 15 In this example, another modified interface biomolecule is illustrated. The fragment B domain of protein A is attached to the first 32 amino acids of fragment 1 of human factor II. There are 10 Gla residues located at positions 6, 7, 14, 16, 19, 20, 25, 26, 29 and 32 of the fragment 1 protein. The modified molecule as generated in a computer model is shown in FIG. 21. The sequence listing of the modified molecule is provided in SEQ ID NO: 12. This is based on the fragment 1-fragment B structure with a 2.2 nm 3 This allows the formation of carboxy-rich domains of 1 nm, which can be bonded to the alumina substrate. 3 This results in a carboxy-rich domain with 9.09 carboxy groups per unit area. The surface charge map of the 3D structure of protein A fragment B bound to the first 32 amino acids of human factor II fragment 1 (Figure 22) shows the basic surface charge density of the engineered molecule for binding to an alumina substrate.
[0125] Example 16 Gla sequences containing one or more of the Gla domains from Factor II, Factor VII, Factor X, Factor II with a kringle domain, Protein C, Protein Z, and synthetic peptide sequences with a carboxy-rich domain (see U.S. Pat. No. 9,694,048 to Bauzon et al.) were cloned into each of the Fc fragments of IgG (anti-Gaussia luciferase). The cloning technique used was standard Fc modification techniques at the Centre for Commercialization of Antibodies and Biologics at the University of Toronto (Liu et al.). Gla domains from such proteins or synthetic peptides were cloned as 1-3 units, so that 1, 2 or 3 Gla domains from the proteins were present in each of the Fc fragments of the IgG biomolecule. These are designated Gla 1x, Gla 2x or Gla 3x in Table 2. The cloning technique used a flexible linker sequence (Gly-Gly-Gly-Gly-Ser, as shown in SEQ ID NO:20) and an open reading frame (SEQ ID NO:21) to attach the Gla domain to the Fc fragment. Also, when more than one is attached per heavy chain of the Fc fragment, a flexible linker sequence was used to attach the Gla domain. Other linkers and ORFs are known in the art and may be used. The cloning technique used the subclone 4275hG1, where hG1 refers to the Ab isotype, expressed as (i.e., human IgG1), and 4275 is an antibody that specifically binds Gaussian luciferase and is used as a standard negative control in in vivo studies with this mammal (Liu et al.). The cloning allowed the Gla sequence to be attached to the carboxyl group of both heavy chains of the Fc fragment. R Thus, Gla 1x listed in Table 2 had two Gla domains, Gla 2x had four Gla domains, and Gla 3x had six Gla domains cloned into the Fc fragment of IgG. All clones were expressed in a volume of 10 ml. In this format, the native Gla domain sequence was utilized in each case.。
[0126] [Table 2]
[0127] Example 17 This example illustrates the strong color change caused by the immobilized modified antibody of Example 16 for various initial sputtered aluminum thicknesses. Thin film devices were formed by sputtering a 200 nm thick tantalum layer onto a substrate followed by aluminum layers ranging from 90 to 140 nm thick. The thin metal film was then anodized by applying a constant potential of 4 V in a mixed electrolyte containing 0.4 M phosphoric acid and 0.1 M oxalic acid. Upon removal from the electrolytic bath, the surface was rinsed thoroughly with deionized water. The device surface was subsequently exposed to a protein solution of native prothrombin (0.004 mg) and recombinant IgG modified with the Gla domain of the Fc region as described in Example 16 (Table 2). After 30 minutes of protein exposure, the solution was removed, rinsed with deionized water and air-dried. When viewed at 75 degrees from normal, the modified IgG (Gla 1x) (approximately 150 kDa) produced a strong color change on the device surface, regardless of alumina thickness, when viewed at 75 degrees from normal, similar to native prothrombin. As the number of cloned Gla units increased from 1-3, the ability to produce a color change decreased, such that for the Gla 3x modified antibody, the color change was only slightly visible to the human eye, but as shown above, other detection techniques can be used. These color changes indicate that the modified protein can be successfully immobilized on alumina thicknesses tailored to the purpose, and that the modified protein produces a variety of color changes in the primary and secondary color regions.
[0128] Example 18 This example illustrates that the modified antibody of Example 16 was immobilized on a surface by the Gla modification of Example 16, while the IgG molecules did not naturally cause a visible color change. The surface coated with the modified human antibody of Example 16 was subsequently coated with a solution of either goat anti-human (GAH) IgG (0.02 mg) or goat anti-mouse (GAM) IgG (0.02 mg). Exposure of the GAH IgG (positive control) to the spots with the immobilized modified antibody caused an increase in color change, whereas exposure of the GAM IgG (negative control) to the spots with the immobilized modified human antibody did not cause a visible color change. Additionally, when both GAH and GAM solutions were exposed to the bare device surface for 30 minutes, neither solution caused a color change. This clearly demonstrated a color change due to the formation of a secondary IgG layer when GAH detects the adsorbed recombinant antibody on the surface.
[0129] Example 19 This example illustrates the strong color change that occurred when the immobilized modified antibody of Example 16 was exposed to its specific antigen, Gaussian luciferase. A thin film device was formed by sputtering a 200 nm thick layer of tantalum onto a silicon substrate, followed by a 110 nm thick layer of aluminum. The thin metal film was then anodized by application of a constant potential of 4 V in a mixed electrolyte containing 0.4 M phosphoric acid and 0.1 M oxalic acid. Upon removal from the electrolytic bath, the surface was rinsed thoroughly with deionized water. The device surface was subsequently exposed to a protein solution of native prothrombin (0.004 mg) and recombinant IgG (anti-Gaussian luciferase) modified with the Gla domain of the Fc region (Factor VII Gla 1x) as described in Example 16. After 30 minutes of protein exposure, the solution was removed, rinsed with deionized water and air-dried. The modified IgG (approximately 150 kDa) caused a strong color change (light purple) on the device surface when viewed at 75 degrees from normal, similar to native prothrombin. The surface was then exposed to a 0.2 mg / ml solution of fragment 1 from prothrombin (Factor II) to cap any active sites on the surface. After rinsing with distilled water and drying, no further color change was observed. Solutions of Gaussian luciferase (0.2 mg / ml) or procalcitonin (0.2 mg / ml) were then exposed to the surface for 30 minutes, followed by rinsing and drying. The surface with the modified IgG exposed to Gaussian luciferase turned blue-purple, whereas the surface exposed to procalcitonin did not change color. The surface treated with prothrombin did not change color with either Gaussian luciferase or procalcitonin. Such a color change indicates that the modified proteins can be successfully immobilized on the alumina surface and produce a color change upon exposure to their specific antigen. The modified and immobilized antibodies retain this functionality.
[0130] [Incorporation by Reference and Transformation] All references throughout this application, for example, patent documents, patent application publications, and non-patent literature or other materials, including issued or granted patents or equivalents, are hereby incorporated by reference in their entirety herein, as if each reference were individually incorporated by reference, unless each reference is at least partially inconsistent with the present disclosure of this application (e.g., a partially inconsistent reference is incorporated by reference except for the portion of the partially inconsistent reference).
[0131] The terms and expressions used in this specification are used as descriptive and non-limiting terms, and there is no intention in the use of such terms and expressions to exclude any equivalents of the indicated and described features or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, although the present invention has been disclosed in detail in preferred embodiments, it should be understood that modifications and variations of the exemplary embodiments and any features, concepts disclosed herein may be used by those skilled in the art, and such modifications and variations are considered to be within the scope of the present invention, as defined by the appended claims. The specific embodiments provided herein are examples of useful embodiments of the present invention, and it is clear to those skilled in the art that the present invention can be carried out using many variations of the devices, device components, and method steps presented herein. As is clear to those skilled in the art, the methods and devices useful for the methods may include many optional components and processing elements and steps.
[0132] Whenever a range is given herein, for example, a temperature range, a time range, a size range, or a composition or density range, all intermediate and subranges, as well as all individual values contained within a given range, are intended to be included in the disclosure. It is understood that any subrange or individual value within a range or subrange contained in the present specification may be excluded from the scope of the present claims.
[0133] All patents and publications mentioned in this specification are indicative of the level of ordinary skill in the art to which this invention pertains. References cited in this specification are incorporated herein by reference in their entirety and are intended to represent the state of the art as of the publication date or filing date, and this information is available herein, and, where appropriate, to exclude certain embodiments that exist in the prior art. For example, when claiming a composition of matter, it should be understood that compounds known and available in the art prior to the applicant's invention, including compounds that provide disclosure in the references cited herein, are not intended to be included in the composition of matter claimed herein.
[0134] As used herein, "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended, not excluding further unrecited elements or method steps. As used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim element. As used herein, "consisting essentially of" does not exclude materials or steps that materially affect the basic and novel characteristics of the claim. In any instance herein, any of the terms "comprising," "essentially consisting of," and "consisting of" may be substituted with any of the other two terms. The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation, or limitations not specifically described herein.
[0135] Those skilled in the art will understand that starting materials, biological materials, reagents, synthesis methods, purification methods, analysis methods, assay methods, and biological methods other than those specifically exemplified can be used in the practice of the present invention without undue experimentation. All functional equivalents known in the art of any such materials and methods are intended to be included in the present invention. The terms and expressions used are used as descriptive and non-limiting terms, and there is no intention in the use of such terms and expressions to exclude any equivalents of the indicated and described features or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, although the present invention has been disclosed in detail by preferred embodiments and optional features, it should be understood that modifications and variations of the concepts disclosed herein may be used by those skilled in the art, and such modifications and variations are considered to be within the scope of the present invention as defined by the appended claims. [References] Further embodiments Further embodiments are as follows. [Embodiment 1] 1. A device for use in binding to an analyte of interest, comprising: Aluminum oxide surface, Molecular volume: 2.2-25 nm 3 an interfacial molecule comprising a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, said free carboxyl groups being provided by amino acids comprising two or more carboxy groups, thereby immobilizing said interfacial molecule to said aluminum oxide surface; and i) a cross-linking agent bound to the interface molecule for binding to the analyte; ii) a biomolecule specific for the analyte, bound to the interface molecule by one or more covalent bonds; iii) a biomolecule in the form of an engineered antibody that binds to the interface molecule via a first antigenic determinant specific for the interface molecule and has a second antigenic determinant specific for the analyte; and iv) a biomolecule in the form of a modified antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte. One of Including, the device. [Embodiment 2] 1. An interfacial complex capable of being immobilized on an aluminum oxide surface for use in binding to an analyte of interest, comprising: Molecular volume: 2.2-25 nm 3 an interfacial molecule comprising a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, said free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby being capable of being immobilized on an aluminum oxide surface; and i) a cross-linking agent bound to said interfacial molecule for binding to an analyte of interest; ii) a biomolecule specific for the analyte of interest, bound to the interface molecule by one or more covalent bonds; iii) a biomolecule in the form of an engineered antibody that binds to the interface molecule via a first antigenic determinant specific for the interface molecule and has a second antigenic determinant specific for an analyte of interest; and iv) a biomolecule in the form of an engineered antibody that binds to the interfacial molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. One of An interface complex comprising: [Embodiment 3] 1. A diagnostic system or kit for testing whether binding has occurred to an analyte of interest, comprising: Aluminum oxide surface, Molecular volume: 2.2-25 nm 3 an interfacial molecule comprising a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, said free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby being capable of being immobilized on said aluminum oxide surface; and i) a cross-linking agent bound to the interface molecule for binding to the analyte; ii) a biomolecule specific for the analyte, bound to the interface molecule by one or more covalent bonds; iii) a biomolecule in the form of an engineered antibody that binds to the interface molecule via a first antigenic determinant specific for the interface molecule and has a second antigenic determinant specific for the analyte; and iv) a biomolecule in the form of a modified antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte. One of Including, the interfacial molecule and one of (i), (ii), (iii) and (iv) are immobilized on the aluminum oxide surface; or A diagnostic system or kit, wherein the interfacial molecule and one of (i), (ii), (iii) and (iv) are formed as an interfacial complex and contacted with an analyte prior to immobilization on the aluminum oxide surface. [Embodiment 4] the aluminum oxide surface is formed on a reflective metal capable of developing color when coated with a porous layer of aluminum oxide; the aluminum oxide surface is a porous anodized surface; 4. The diagnostic system or kit of embodiment 3, wherein when contacted with a sample to test for the analyte, a color change is detected upon binding of the analyte to either the crosslinker in the presence of (i) or the biomolecule in the presence of (ii), (iii), or (iv), indicating the presence of the analyte. [Embodiment 5] 1. A method for testing whether binding has occurred to an analyte of interest, comprising: a) forming an aluminum oxide surface having immobilized interfacial molecules, the interfacial molecules having a molecular volume of 2.2 to 25 nm 3 a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby immobilizing the interfacial molecule on the aluminum oxide surface, the interfacial molecule comprising: i) a cross-linking agent for binding to the analyte; ii) a biomolecule specific for said analyte; iii) a biomolecule in the form of an engineered antibody having a first antigenic determinant specific for said interface molecule and a second antigenic determinant specific for said analyte of interest; and iv) a biomolecule in the form of an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. a step, b) contacting the surface of a) with a sample to test for the analyte; and c) detecting the presence of said analyte upon binding of said analyte to said surface of a). A method comprising: [Embodiment 6] 1. A method for testing whether binding has occurred to an analyte of interest, comprising: a) forming an aluminum oxide surface; b) forming an interfacial complex capable of bonding to the aluminum oxide surface, the interfacial complex having a molecular volume between 2.2 and 25 nm 3 the interfacial molecule comprises a polypeptide having at least one carboxy-rich domain providing at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids containing two or more carboxy groups, thereby allowing the interfacial molecule to be immobilized on the aluminum oxide surface, the interfacial molecule comprising: i) a cross-linking agent for binding to the analyte; ii) a biomolecule specific for said analyte; iii) a biomolecule in the form of an engineered antibody having a first antigenic determinant specific for said interface molecule and a second antigenic determinant specific for said analyte of interest; and iv) a biomolecule in the form of an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. a step, b) contacting the interfacial complex of a) with a sample to test for the analyte; c) contacting the sample and the interfacial complex of b) with the aluminum oxide surface; and d) detecting the presence of the analyte upon binding of the analyte and the interfacial complex to the aluminum oxide surface. A method comprising: [Embodiment 7] the aluminum oxide surface is formed on a reflective metal capable of developing color when coated with a porous layer of aluminum oxide; the aluminum oxide surface is a porous anodized surface; 7. The method of embodiment 5 or 6, wherein when contacted with a sample to test for the analyte, a color change is detected upon binding of the analyte to either the crosslinker in the presence of (i), or the biomolecule in the presence of (ii), (iii), or (iv), indicating the presence of the analyte. [Embodiment 8] The carboxy-rich domain is Molecular volume: 2.2-25 nm 3 At least 10 free carboxyl groups in Molecular volume: 2.2-25 nm 3 At least 20 free carboxyl groups in Molecular volume: 2.2-17 nm 3 At least 10 free carboxyl groups in Molecular volume: 2.2-17 nm 3 At least 20 free carboxyl groups in Molecular volume: 7.0-17 nm 3 At least 10 free carboxyl groups in Molecular volume: 7.0-17 nm 3 At least 20 free carboxyl groups in The device, interface complex, diagnostic system, kit or method according to any one of embodiments 1 to 7, [Embodiment 9] the cross-linking agent is covalently bonded to the interfacial molecule; or The biomolecule is covalently attached to the interface molecule by a crosslinker; or The interface molecule and the biomolecule are modified in amino acid sequence such that the interface molecule and the biomolecule are linked by a peptide bond; or the interface molecule is an engineered or synthetic protein, polypeptide or antibody incorporating a carboxy-rich domain; or the biomolecule is an engineered antibody having a first antigenic determinant specific for the interface molecule and a second antigenic determinant specific for the analyte of interest; or The biomolecule is an engineered antibody that binds to the interface molecule via an Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. A device, interface complex, diagnostic system, kit or method according to any one of embodiments 1 to 8. [Embodiment 10] The device, diagnostic system, kit or method of any one of embodiments 1 to 9, wherein the interfacial molecules are formed on the aluminum oxide surface as a continuous or discontinuous coating, as delineated dots or lines, or as an array. [Embodiment 11] The device, diagnostic system, kit or method of embodiment 10, wherein the interfacial molecules comprise different types of interfacial molecules spaced apart on the aluminum oxide surface, and the biomolecule is bound to one type of the interfacial molecules, or specific biomolecules are bound to the various interfacial molecules such that different specific biomolecules are bound to each type of interfacial molecule. [Embodiment 12] 12. The device, diagnostic system, kit or method of any one of the preceding embodiments, wherein the aluminum oxide surface is formed on a substrate in the form of a particle, powder, thin film, slide, strip, filter, bead, magnetic bead, magnetic particle or coating. [Embodiment 13] 13. The device, diagnostic system, kit or method of any one of embodiments 1 to 12, wherein the aluminum oxide surface is formed by sputtering, evaporating, casting or extruding aluminum metal or an aluminum alloy, which is further anodized to form a porous anodized aluminum oxide surface. [Embodiment 14] 13. The device, diagnostic system, kit or method of any one of embodiments 1 to 12, wherein the aluminum oxide surface is formed on the substrate by RF sputtering, reactive sputtering or chemical vapor deposition of aluminum oxide. [Embodiment 15] 15. The device, diagnostic system, kit or method of any one of embodiments 1 to 14, wherein the interfacial molecules or the interfacial complexes are immobilized as a coating on the aluminum oxide surface from a solution of the interfacial molecules in a suitable solvent, and then the solution is removed. [Embodiment 16] The device, interface complex, diagnostic system, kit or method of any one of embodiments 1 to 14, wherein the interface molecule comprises one or more of the amino acids selected from the group consisting of aspartic acid (Asp), glutamic acid (Glu), and gamma-carboxyglutamic acid (Gla). [Embodiment 17] The device, interface complex, diagnostic system, kit or method of any one of embodiments 1 to 14, wherein the interface molecule is a vitamin K dependent protein, a fragment thereof comprising a Gla domain, or a fragment thereof comprising a modified Gla domain. [Embodiment 18] The device, interface complex, diagnostic system, kit or method described in any one of embodiments 1 to 14, wherein the interface molecule and the biological molecule are formed as molecules modified so that the carboxy-rich domain is contained in a protein, polypeptide, antigen, antibody, carbohydrate, aptamer or lipid. [Embodiment 19] The device, interface complex, diagnostic system, kit or method of embodiment 18, wherein the carboxy-rich domain comprises one or more Gla domains of a vitamin K dependent protein or a fragment or derivative thereof, and the modified molecule comprises Protein A, fragment B of Protein A or an IgG molecule. [Embodiment 20] 15. The device, interface complex, diagnostic system, kit or method of any one of embodiments 1 to 14, wherein the interface molecule is a protein, one or more Gla domains of a protein, or a modified Gla domain of a protein, in which one or more of the Gla residues are substituted with Glu, Asp, Glu-Glu, Glu-Asp, Asp-Glu, or Asp-Asp, and the protein is selected from the group consisting of prothrombin, prothrombin fragment 1, protein S, coagulation factor IX, factor X, factor VII, protein C, matrix Gla protein, and bone Gla protein. [Embodiment 21] 15. The device, interface complex, diagnostic system, kit or method of any one of embodiments 1 to 14, wherein the interface molecule is a protein, one or more Gla domains of a protein, or a modified Gla domain of a protein, in which one or more of the Gla residues are substituted with Glu, Asp, Glu-Glu, Glu-Asp, Asp-Glu, or Asp-Asp, and the protein is selected from the group consisting of prothrombin, fragment 1 of prothrombin, protein S, and coagulation factor IX. [Embodiment 22] 22. The device, interface complex, diagnostic system, kit or method of any one of embodiments 1 to 21, wherein the biomolecule is a member of a binding pair selected from the group consisting of antibody-antigen, antibody-hapten, enzyme-substrate, enzyme-receptor, toxin-receptor, protein-protein, avidin-biotin, aptamer-aptamer target, and drug receptor-drug. [Embodiment 23] The device, interface complex, diagnostic system, kit or method of any one of embodiments 1 to 22, wherein the interface molecule and the biological molecule are in the form of an interface complex of an engineered antibody having a Fab fragment that binds to the interface molecule via an Fc fragment of the antibody and is specific for an analyte, and the interface complex comprises one or more of the carboxy-rich domains cloned into the carboxy terminus of each heavy chain of the Fc fragment of the antibody. [Embodiment 24] The device, interface complex, diagnostic system, kit or method of embodiment 23, wherein one or more of the carboxy-rich domains comprise one or more Gla domains of a vitamin K dependent protein, a fragment thereof comprising a Gla domain, or a fragment thereof comprising a modified Gla domain. [Embodiment 25] 25. The device, interface complex, diagnostic system, kit or method of embodiment 24, wherein the antibody is an IgG, the protein is selected from factor II, factor VII, factor X, protein C, protein Z, and the interface complex comprises one or two of the Gla domains cloned into each heavy chain of the Fc fragment. [Embodiment 26] Use of an interfacial molecule to refunctionalize an aluminum oxide surface for use in biomedical applications, the interfacial molecule having a molecular volume between 2.2 and 25 nm 3 The method comprises the steps of: (a) providing a polypeptide having at least one carboxy-rich domain that provides at least five free carboxyl groups therein, the free carboxyl groups being provided by amino acids that contain two or more carboxy groups, thereby enabling the interfacial molecule to be immobilized on the aluminum oxide surface;
Claims
1. 1. A diagnostic system or kit for testing whether binding has occurred to an analyte of interest, comprising: A substrate having an aluminum oxide surface; Molecular volume: 2.2-25 nm 3 an interfacial molecule comprising a polypeptide having at least one carboxy-rich domain containing at least five free carboxyl groups therein, the density of free carboxyl groups in said carboxy-rich domain being between 1.15 and 9.09 / nm 3 , said free carboxyl groups being provided by amino acids containing two or more carboxyl groups; i) a cross-linking agent bound to the interface molecule for binding to the analyte; ii) a biomolecule specific for the analyte, bound to the interface molecule by one or more covalent bonds; iii) a biomolecule in the form of an engineered antibody that binds to the interface molecule via a first antigenic determinant specific for the interface molecule and has a second antigenic determinant specific for the analyte; and iv) a biomolecule in the form of an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte. One of Including, the interfacial molecule and one of (i), (ii), (iii) and (iv) are immobilized on the aluminum oxide surface; or the interfacial molecule and one of (i), (ii), (iii) and (iv) are formed as an interfacial complex and contacted with an analyte prior to immobilization on the aluminum oxide surface; When contacted with a sample and tested for said analyte, when (i) is present, the presence of the analyte is detected upon binding of the analyte to the cross-linker; A diagnostic system or kit, wherein when (ii), (iii) or (iv) is present, the presence of said analyte is detected upon binding of said analyte to any of said biomolecules.
2. the aluminum oxide surface is formed on a reflective metal capable of developing color when coated with a porous layer of aluminum oxide; the aluminum oxide surface is a porous anodized surface; When contacted with a sample and tested for said analyte, when (i) is present, a color change is detected upon binding of the analyte to the cross-linker; when (ii), (iii) or (iv) is present, a color change is detected upon binding of the analyte to any of the biomolecules; The diagnostic system or kit of claim 1 , wherein the color change indicates the presence of the analyte.
3. 1. A method for testing whether binding has occurred to an analyte of interest, comprising: a) providing a substrate having an aluminum oxide surface; b) forming an interface molecule, the interface molecule having a molecular volume of 2.2 to 25 nm 3 a polypeptide having at least one carboxy-rich domain containing at least five free carboxyl groups therein, the density of free carboxyl groups in said carboxy-rich domain being 1.15-9.09 / nm 3 , said free carboxyl groups being provided by amino acids containing two or more carboxyl groups, said interface molecule being i) a cross-linking agent for binding to the analyte; ii) a biomolecule specific for said analyte; iii) a biomolecule in the form of an engineered antibody having a first antigenic determinant specific for said interface molecule and a second antigenic determinant specific for said analyte of interest; and iv) a biomolecule in the form of an engineered antibody that binds to the interface molecule via the Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. a step of: c) immobilizing the interfacial molecule and one of (i), (ii), (iii) and (iv) on the aluminum oxide surface or forming an interfacial complex from the interfacial molecule and one of (i), (ii), (iii) and (iv). d) contacting the aluminum oxide surface of c) or the interfacial complex of c) with a sample to test for the analyte; and e) detecting the presence of the analyte upon binding of c) to the aluminum oxide surface or upon binding of the analyte and the interfacial complex to the aluminum oxide surface. A method comprising:
4. the aluminum oxide surface is formed on a reflective metal capable of developing color when coated with a porous layer of aluminum oxide; the aluminum oxide surface is a porous anodized surface; 4. The method of claim 3, wherein when contacted with the sample to test for the analyte, a color change is detected upon binding of the analyte to either the crosslinker in the presence of (i), or the biomolecule in the presence of (ii), (iii) or (iv), indicating the presence of the analyte.
5. The carboxy-rich domain has a molecular volume of 2.2 to 25 nm 3 3. The diagnostic system or kit of claim 1 or 2, comprising at least 10 free carboxyl groups therein.
6. The diagnostic system or kit of claim 1, wherein the carboxy-rich domain contains at least 20 free carboxyl groups within a molecular volume of 2.2 to 25 nm 3 .
7. The diagnostic system or kit of claim 1, wherein the carboxy-rich domain contains at least 10 free carboxyl groups within a molecular volume of 2.2 to 17 nm 3 .
8. The diagnostic system or kit of claim 1, wherein the carboxy-rich domain contains at least 20 free carboxyl groups within a molecular volume of 2.2 to 17 nm 3 .
9. The diagnostic system or kit according to claim 1, wherein the carboxy-rich domain contains at least 10 free carboxyl groups within a molecular volume of 7.0 to 17 nm 3 .
10. The diagnostic system or kit of claim 1 or 2, wherein the carboxy-rich domain contains at least 20 free carboxyl groups within a molecular volume of 7.0 to 17 nm 3 .
11. The diagnostic system or kit according to claim 1 or 2, wherein the carboxy-rich domain contains 10 to 24 free carboxyl groups within a molecular volume of 2.2 to 17 nm 3 .
12. the cross-linking agent is covalently bonded to the interfacial molecule; or The biomolecule is covalently attached to the interface molecule by a crosslinker; or The interface molecule and the biomolecule are modified in amino acid sequence such that the interface molecule and the biomolecule are linked by a peptide bond; or the interface molecule is an engineered or synthetic protein, polypeptide or antibody incorporating a carboxy-rich domain; or the biomolecule is an engineered antibody having a first antigenic determinant specific for the interface molecule and a second antigenic determinant specific for the analyte of interest; or The biomolecule is an engineered antibody that binds to the interface molecule via an Fc fragment of the antibody and has a Fab fragment specific for the analyte of interest. A diagnostic system or kit according to claim 1 or 2.
13. The interfacial molecules are formed on the aluminum oxide surface as a continuous or discontinuous coating, as delineated dots or lines, or as an array; the interfacial molecules comprise different types of interfacial molecules spaced apart on the aluminium oxide surface, the biomolecule being bound to one type of the interfacial molecules, or specific biomolecules being bound to different types of interfacial molecules such that different specific biomolecules are bound to each type of interfacial molecule; and / or the aluminum oxide surface is formed on a substrate in the form of a particle, a powder, a thin film, a slide, a strip, a filter, a bead, a magnetic bead, a magnetic particle or a coating; A diagnostic system or kit according to claim 1 or 2.
14. The aluminum oxide surface is formed by sputtering, evaporating, casting or extruding aluminum metal or an aluminum alloy, which is further anodized to form a porous anodized aluminum oxide surface; or The aluminum oxide surface is formed on a substrate by RF sputtering, reactive sputtering or chemical vapor deposition of aluminum oxide. A diagnostic system or kit according to claim 1 or 2.
15. 3. The diagnostic system or kit of claim 1 or 2, wherein the interfacial molecules or the interfacial complexes are immobilized as a coating on the aluminum oxide surface from a solution of the interfacial molecules in a suitable solvent, and then the solution is removed.
16. the carboxy-rich domain of the interface molecule comprises one or more of the amino acids selected from the group consisting of aspartic acid (Asp), glutamic acid (Glu), and gamma-carboxyglutamic acid (Gla); the interface molecule is a vitamin K dependent protein, a fragment thereof comprising a Gla domain, or a fragment thereof comprising a modified Gla domain, in which one or more of the Gla residues are replaced with Glu, Asp, Glu-Glu, Glu-Asp, Asp-Glu, or Asp-Asp; or The interface molecule and the biomolecule are formed as molecules modified so that the carboxy-rich domain is contained in a protein, a polypeptide, an antigen, an antibody, a carbohydrate, an aptamer, or a lipid. A diagnostic system or kit according to claim 1 or 2.
17. 17. The diagnostic system or kit of claim 16, wherein the carboxy-rich domain comprises one or more Gla domains of a vitamin K dependent protein or a fragment thereof comprising one or more Gla domains, and the modified molecule comprises protein A, fragment B of protein A or an IgG molecule.
18. 3. The diagnostic system or kit of claim 1 or 2, wherein the interface molecule is a protein, one or more Gla domains of a protein, or a modified Gla domain of a protein, in which one or more of the Gla residues are substituted with Glu, Asp, Glu-Glu, Glu-Asp, Asp-Glu, or Asp-Asp, and the protein is selected from the group consisting of prothrombin, prothrombin fragment 1, protein S, coagulation factor IX, factor X, factor VII, protein C, matrix Gla protein, and bone Gla protein.
19. 3. The diagnostic system or kit of claim 1 or 2, wherein the biomolecule is a member of a binding pair selected from the group consisting of antibody-antigen, antibody-hapten, enzyme-substrate, enzyme-receptor, toxin-receptor, protein-protein, avidin-biotin, aptamer-aptamer target, and drug receptor-drug.
20. The diagnostic system or kit of claim 1 or 2, wherein the interface molecule and the biological molecule are in the form of an interface complex of an engineered antibody having a Fab fragment that binds to the interface molecule via an Fc fragment of the antibody and is specific for an analyte, and the interface complex comprises one or more of the carboxy-rich domains attached to the carboxyl terminus of each heavy chain of the Fc fragment of the antibody.
21. one or more of said carboxy-rich domains comprise one or more Gla domains of a vitamin K dependent protein, a fragment thereof comprising a Gla domain, or a fragment thereof comprising a modified Gla domain, wherein one or more of the Gla residues in said modified Gla domain are replaced with Glu, Asp, Glu-Glu, Glu-Asp, Asp-Glu, or Asp-Asp; the antibody is an IgG, the protein is selected from factor II, factor VII, factor X, protein C, protein Z, and the interface complex comprises one or two of the Gla domains cloned into each heavy chain of the Fc fragment; 21. The diagnostic system or kit of claim 20.
22. Use of an interfacial molecule for refunctionalizing a substrate having an aluminum oxide surface for use in biomedical applications, the interfacial molecule having a molecular volume between 2.2 and 25 nm 3 The polypeptide comprises at least one carboxy-rich domain having at least five free carboxyl groups therein, wherein the density of free carboxyl groups in said carboxy-rich domain is between 1.15 and 9.09 / nm 3 , and said free carboxyl groups are provided by amino acids containing two or more carboxyl groups.
Citation Information
Patent Citations
Kit for immobilizing organic material, structure in which organic material is immobilized and method for producing the same structure
JP2005204609A
Gla domain as a targeting agent
JP2016516037A
Tripodal functional interface molecule for immobilization of biological molecule and device for detection of gene
WO2006104035A1
Method for affixing antibodies to self-assembled monolayer
WO2012168988A1
